Renal Cell Carcinoma
Renal cell carcinoma is a malignant neoplasm arising from the renal tubular epithelium, most commonly the clear cell subtype, typically presenting in adults with hematuria, flank pain, or a palpable mass.
Renal Cell Carcinoma (RCC) — Definition, Epidemiology, Risk Factors, Anatomy, Etiology, Pathophysiology, Classification & Clinical Features
Renal cell carcinoma (RCC) is a malignant neoplasm arising from the renal tubular epithelium (i.e., the renal cortex/parenchyma). Let's break down the name:
- Renal = kidney (Latin: ren)
- Cell = referring to the epithelial cells lining the renal tubules
- Carcinoma = malignant tumour of epithelial origin (Greek: karkinos = crab, -oma = tumour)
So "renal cell carcinoma" literally tells you: a cancer of the epithelial cells of the kidney. This distinguishes it from urothelial carcinoma of the renal pelvis (which arises from transitional epithelium), nephroblastoma (embryonic tissue), and renal sarcomas (mesenchymal origin).
RCC is the most common primary renal neoplasm, accounting for 80–85% of all primary renal neoplasms [1][2][3].
It is notoriously called the "internist's tumour" because of its protean manifestations — it can present with almost anything due to paraneoplastic syndromes, and is also called the "great mimic."
2. Epidemiology
- RCC accounts for approximately 2–4% of all adult cancers, with ~214,000 new cases per year worldwide [3].
- In Hong Kong: incidence ~4.8/100,000; mortality ~1.6/100,000 [3].
- Incidence has been rising globally, partly due to increased use of cross-sectional imaging (CT/USG) detecting incidental small renal masses — the so-called "incidentaloma" effect.
| Factor | Detail |
|---|---|
| Sex | Male predominance (M:F ≈ 1.5–2:1) [2][3] — androgens may promote tumour growth, and males have higher rates of smoking and occupational exposures |
| Age | 6th–8th decade of life (median age of diagnosis = 64 years) [2][3] |
| Ethnicity | Less common in Asians compared to Western populations [3]; higher in African Americans in the US |
| Type | Proportion | Origin |
|---|---|---|
| Renal cell carcinoma | 80–85% | Renal cortex (tubular epithelium) |
| Urothelial (transitional cell) carcinoma | ~8% | Renal pelvis |
| Nephroblastoma (Wilms' tumour) | 5–6% | Embryonic nephrogenic tissue (children) |
| Others | Rare | Oncocytoma, sarcomas, etc. |
High Yield — Incidental Detection
50–60% of RCC cases are now discovered incidentally on imaging (e.g., abdominal USG or CT done for other reasons) [4]. This means the majority of patients are asymptomatic at presentation. The classic triad of haematuria, flank pain, and palpable mass is seen in only 10–20% — and when present, usually indicates advanced disease.
3. Relevant Anatomy and Function
Understanding the anatomy is critical because it explains patterns of spread and clinical features.
- The kidney has two functional zones:
- Cortex (outer) — contains glomeruli and proximal/distal convoluted tubules → this is where RCC arises
- Medulla (inner) — contains loops of Henle and collecting ducts
- The renal pelvis (funnel-shaped structure collecting urine) is lined by urothelium — this is where urothelial carcinoma arises (distinct from RCC)
This is where things get interesting and clinically important:
- Renal arteries → branch from the aorta at L1–L2 level
- Renal veins → drain directly into the IVC
- The left renal vein is longer, crosses anterior to the aorta, and receives the left gonadal (testicular/ovarian) vein and the left adrenal vein
- The right renal vein is shorter, draining directly into the IVC; the right gonadal vein drains directly into the IVC (not via the renal vein)
Why does this matter?
RCC has a unique propensity to invade the renal vein and extend as a tumour thrombus into the IVC, and even into the right atrium. This is almost pathognomonic for RCC among solid organ cancers.
- Left-sided RCC invading the left renal vein → obstructs drainage of the left gonadal vein → left-sided varicocele (this is a classic exam pearl!) [4]
- IVC invasion → bilateral lower limb oedema, ascites, hepatomegaly (Budd-Chiari-like picture), and even pulmonary embolism if tumour thrombus dislodges [4]
- Para-aortic and paracaval lymph nodes (retroperitoneal lymph nodes)
- Most common site of regional metastasis: retroperitoneal lymph nodes [2]
RCC metastasises via:
- Haematogenous spread (most important — via the renal vein → IVC → systemic circulation)
- Lymphatic spread (retroperitoneal nodes)
- Direct invasion (perinephric fat, adrenal gland, adjacent structures)
Most common sites of distant metastasis: lung (most common, ~50–60%), bone, liver, brain, lymph nodes [2][4]
Why does RCC love to metastasise to the lung?
Because the venous drainage of the kidney goes directly into the IVC → right heart → pulmonary arteries → lungs. This is the first capillary bed that tumour emboli encounter. This is exactly the same reason liver cancers also commonly metastasise to the lungs (hepatic veins → IVC → lungs). The lung is the "first filter" for venous drainage from the kidney.
- The kidney is enclosed within Gerota's fascia (perirenal fascia), which forms a natural anatomical barrier.
- Tumour confined within Gerota's fascia has a better prognosis (T1–T3a) than tumour breaching it (T4).
- This is why radical nephrectomy removes the kidney along with Gerota's fascia, the perirenal fat, and ipsilateral adrenal (if involved).
4. Etiology and Risk Factors
RCC is a multifactorial disease. Risk factors can be organised by the surgical sieve or, more practically for clinical clerking, by history-taking categories:
4.2 Modifiable Risk Factors
- Smoking is a major risk factor: RR ≈ 1.31 (all smokers), 1.36 (current smokers), 1.16 (ex-smokers) [1][3]
- Also associated with more advanced disease at presentation [3]
- Mechanism: Tobacco smoke contains nitrosamines and polycyclic aromatic hydrocarbons that are filtered by the kidney, causing direct mutagenic damage to tubular epithelial cells. Smoking also causes chronic tissue hypoxia, which upregulates hypoxia-inducible factor (HIF) — the same pathway involved in VHL-related RCC (see pathophysiology below).
- Obesity is an independent risk factor [1][2]
- Mechanism: Multiple pathways:
- Increased circulating insulin and IGF-1 (mitogenic)
- Chronic inflammation (adipokines, IL-6, TNF-α)
- Altered sex hormone metabolism (higher oestrogen levels)
- Lipid peroxidation causing oxidative DNA damage in renal tubular cells
- Hypertension is a risk factor [1][2]
- Mechanism: Unclear, but hypotheses include:
- Chronic renal hypoxia from arteriolar damage → HIF upregulation
- Increased ROS (reactive oxygen species) damaging tubular DNA
- Note: antihypertensive medications (especially diuretics) were once implicated, but HTN itself appears to be the independent risk factor
- Heavy and prolonged use of aspirin, paracetamol (acetaminophen), and NSAIDs [2][3]
- Mechanism: Chronic analgesic use → analgesic nephropathy → chronic tubular injury and regenerative proliferation → increased mutation risk. Similar mechanism to why chronic inflammation predisposes to cancer elsewhere.
4.3 Medical Risk Factors
- Acquired polycystic kidney disease (due to chronic dialysis): 30× risk of RCC [1][2][3]
- Require yearly USG screening [3]
- Key distinction: These kidneys are small to normal in size (unlike ADPKD where kidneys are enlarged) [2]
- Mechanism: Chronic uraemia → cyst formation → epithelial dysplasia within cysts → malignant transformation. The cystic environment promotes genomic instability.
Acquired Cystic Kidney Disease vs. ADPKD
Students often confuse these. Acquired cystic kidney disease occurs in patients on long-term dialysis (haemo- or peritoneal), and kidneys are small to normal in size. ADPKD is a genetic condition with large kidneys. Both can develop RCC, but the dialysis-associated risk is much more dramatic (30× increase).
- Associated immunosuppression increases RCC risk [2]
- Mechanism: Immunosuppressive drugs (e.g., CNIs, mycophenolate) reduce immune surveillance against nascent tumour cells. This is a general principle: immunosuppression → reduced immune editing → cancer.
- Mechanism likely relates to chronic inflammation and possibly direct viral effects on renal epithelium.
D. Sickle Cell Disease — specifically associated with renal medullary carcinoma (a very aggressive subtype) [3][5]
- Chronic inflammation and irritation of renal epithelium.
- Direct DNA damage from radiation and alkylating agents.
Genetic predisposition: Family history and inherited syndromes such as von Hippel-Lindau, Birt-Hogg-Dubé, hereditary papillary RCC, and tuberous sclerosis [1].
Hereditary RCC accounts for ~5% of cases but is disproportionately important because:
- These patients present younger (often < 40 years)
- Tumours are often bilateral and multifocal
- Understanding the genetics teaches us the molecular pathogenesis of sporadic RCC too
| Syndrome | Gene | Chromosome | Inheritance | Associated RCC Subtype | Other Associations |
|---|---|---|---|---|---|
| Von Hippel-Lindau (VHL) | VHL | 3p25 | AD | Clear cell RCC (~40%) | Phaeochromocytoma (14%), cerebellar haemangioblastoma, retinal angiomas, renal cysts (75%), pancreatic cysts/NETs, epididymal cystadenoma [2][3] |
| Hereditary papillary RCC (HPRCC) | MET | 7q31 | AD | Bilateral, multifocal papillary RCC [3] | — |
| Birt-Hogg-Dubé | FLCN (folliculin) | 17p11 | AD | Chromophobe RCC, oncocytoma, hybrid tumours | Fibrofolliculomas (skin), pulmonary cysts, spontaneous pneumothorax |
| Tuberous sclerosis complex (TSC) | TSC1/TSC2 | 9q34/16p13 | AD | RCC develops in < 5% of individuals [3] | Angiomyolipomas (most common renal lesion in TSC), cortical tubers, cardiac rhabdomyomas, LAM |
| Hereditary leiomyomatosis and RCC (HLRCC) | FH (fumarate hydratase) | 1q42 | AD | Aggressive papillary type 2 RCC | Cutaneous and uterine leiomyomas |
5. Pathophysiology
This is the most important pathway to understand because:
- VHL gene mutation is found in ~90% of sporadic clear cell RCC (not just hereditary cases) [3]
- It explains the biology of the tumour and the rationale for targeted therapy
Normal VHL function:
Under normal oxygen conditions (normoxia):
- HIF-α (hypoxia-inducible factor alpha) is hydroxylated by prolyl hydroxylases (oxygen-dependent enzymes)
- Hydroxylated HIF-α is recognised by the VHL protein (pVHL)
- pVHL is part of an E3 ubiquitin ligase complex → tags HIF-α for proteasomal degradation
- Result: HIF-α is kept at low levels → downstream targets are NOT activated
What happens when VHL is lost (mutated/deleted)?
Key downstream effects of HIF-α accumulation:
| Target Gene | Protein | Effect | Clinical Relevance |
|---|---|---|---|
| VEGF | Vascular endothelial growth factor | Angiogenesis — new blood vessel formation | Highly vascular tumour on imaging; target of anti-VEGF therapy (sunitinib, pazopanib, bevacizumab) |
| PDGF | Platelet-derived growth factor | Stromal support, vessel maturation | Target of multi-kinase inhibitors |
| EPO | Erythropoietin | Red cell production | Paraneoplastic polycythaemia |
| TGF-α | Transforming growth factor alpha | Autocrine growth stimulation via EGFR | Tumour proliferation |
| GLUT1 | Glucose transporter 1 | Increased glucose uptake | Warburg effect, FDG-PET avidity |
| CA-IX | Carbonic anhydrase IX | pH regulation | Immunohistochemistry marker for clear cell RCC |
Why "clear cell"?
The clear cytoplasm seen on histology is due to accumulation of lipid and glycogen in the cytoplasm. During histological processing (fixation and staining with H&E), these lipids and glycogen are dissolved out, leaving empty-appearing ("clear") cells. The lipid/glycogen accumulation is driven by HIF-mediated metabolic reprogramming (increased glucose uptake via GLUT1 and altered lipid metabolism).
VHL — The Master Switch
Think of VHL as the "brake pedal" on angiogenesis and cell growth. When VHL is lost, the car (tumour) accelerates uncontrollably. This is why clear cell RCC is one of the most vascular solid tumours — it's essentially pumping out VEGF all the time. This also explains why it responds to anti-angiogenic therapies (TKIs targeting VEGF receptor) and why it's classically resistant to conventional chemotherapy (chemotherapy relies on good blood supply to deliver drugs, but paradoxically, the disordered vasculature in RCC is leaky and dysfunctional).
| RCC Subtype | Key Genetic Alteration | Pathway |
|---|---|---|
| Clear cell | Del(3p), VHL mutation [3] | HIF/VEGF pathway (as above) |
| Papillary Type 1 | Trisomy 7, MET gene activation (7q) [3] | MET/HGF signalling → cell proliferation and motility |
| Papillary Type 2 | Trisomy 16, 17; loss of Y [3]; FH mutations in HLRCC | Fumarate accumulation → HIF stabilisation (pseudohypoxia) |
| Chromophobe | Multiple chromosomal losses (1, 2, 6, 10, 13, 17, 21) | mTOR pathway activation |
RCC is notorious for paraneoplastic phenomena (~6–10% of patients) [4]. The mechanisms are:
| Paraneoplastic Phenomenon | Mechanism | Frequency |
|---|---|---|
| Polycythaemia | Tumour produces EPO (remember: HIF-α drives EPO transcription when VHL is lost) | ~3–5% |
| Hypercalcaemia | Tumour produces PTHrP (parathyroid hormone-related peptide) mimicking PTH; also 1α-hydroxylation of vitamin D by tumour cells | ~13–20% |
| Hypertension (non-renal artery related) | Tumour produces renin → RAAS activation | Uncommon |
| Anaemia of chronic disease | Chronic inflammation (IL-6, hepcidin upregulation) → functional iron deficiency | Common |
| Stauffer syndrome (non-metastatic hepatic dysfunction) | Unknown mechanism — likely cytokine-mediated (IL-6); characterised by abnormal LFTs, hepatosplenomegaly, fever without liver metastases; resolves after nephrectomy | ~3–6% |
| Fever/cachexia | Cytokine production (IL-6, TNF-α) | Common |
Stauffer Syndrome
This is a frequently tested concept. Stauffer syndrome = non-metastatic liver dysfunction in RCC [4]. The LFTs are abnormal (raised ALP, GGT, bilirubin), there is hepatosplenomegaly, but there are no liver metastases on imaging. It is a paraneoplastic phenomenon that reverses after tumour resection. If LFT abnormalities persist post-nephrectomy, think recurrence. Do not mistake it for metastatic disease and deny the patient potentially curative surgery!
6. Classification
The main subtypes and their features [1][5]:
| Subtype | Approximate Incidence | Origin/Histology | Key Features |
|---|---|---|---|
| Clear Cell RCC (ccRCC) | ~70–80% | Proximal tubule epithelial cells | Most common subtype; characterised by clear cytoplasm due to lipid/glycogen; associated with VHL gene mutation; aggressive behaviour [5] |
| Papillary RCC (pRCC) | ~10–15% | Distal tubule epithelial cells | Divided into Type 1 (small basophilic cells, MET gene alterations, better prognosis) and Type 2 (larger eosinophilic cells, worse prognosis); new WHO classifications are evolving [5] |
| Chromophobe RCC | ~5–10% | Distal tubule intercalated cells | Pale eosinophilic cytoplasm with distinct cell membranes; better prognosis than ccRCC [5] |
| Collecting Duct Carcinoma | ~1% | Collecting ducts | Rare, aggressive subtype with poor prognosis [5] |
| Renal Medullary Carcinoma | < 1% | Medullary region; related to sickle cell disease | Very aggressive, mostly in young patients with sickle cell trait [5] |
| Translocation RCC | Rare | Variable; involving TFE3 or TFEB gene translocations | Usually affects children and young adults; distinct molecular pathology [5] |
| Mucinous Tubular and Spindle Cell Carcinoma | Rare | Distal tubule | Indolent behaviour; low metastatic potential [5] |
| Stage | T | Description |
|---|---|---|
| T1a | Tumour ≤ 4 cm, limited to kidney | |
| T1b | Tumour > 4 cm but ≤ 7 cm, limited to kidney | |
| T2a | Tumour > 7 cm but ≤ 10 cm, limited to kidney | |
| T2b | Tumour > 10 cm, limited to kidney | |
| T3a | Tumour extends into renal vein or its segmental branches, or invades perirenal/renal sinus fat, but not beyond Gerota's fascia | |
| T3b | Tumour extends into IVC below diaphragm | |
| T3c | Tumour extends into IVC above diaphragm or invades wall of IVC | |
| T4 | Tumour invades beyond Gerota's fascia (including contiguous extension into ipsilateral adrenal gland) |
| Stage | N | Description |
|---|---|---|
| N0 | No regional lymph node metastasis | |
| N1 | Metastasis in regional lymph node(s) |
| Stage | M | Description |
|---|---|---|
| M0 | No distant metastasis | |
| M1 | Distant metastasis |
Prognostic Stage Grouping:
| Stage | TNM |
|---|---|
| I | T1 N0 M0 |
| II | T2 N0 M0 |
| III | T1–T2 N1 M0 or T3 N0–N1 M0 |
| IV | T4 any N M0 or any T any N M1 |
Key Staging Points for Exams
- T1: ≤ 7 cm, confined to kidney (a ≤ 4 cm, b 4–7 cm) — these are candidates for partial nephrectomy
- T3: renal vein / IVC involvement or perinephric fat invasion (but still within Gerota's) — this is the "tumour thrombus" stage
- T4: beyond Gerota's fascia — locally advanced
- Any M1 = Stage IV regardless of T or N
The grading system has transitioned from the older Fuhrman system to the WHO/ISUP grading system (2013, updated), based on nucleolar prominence:
| Grade | Description | Prognosis |
|---|---|---|
| 1 | Nucleoli absent or inconspicuous at 400× | Best |
| 2 | Nucleoli conspicuous at 400× but inconspicuous at 100× | |
| 3 | Nucleoli conspicuous at 100× | |
| 4 | Extreme nuclear pleomorphism, sarcomatoid/rhabdoid differentiation | Worst |
7. Clinical Features
RCC is usually asymptomatic and presents until disease is advanced [2]. The presentation can be categorised as:
- Incidental (most common today)
- Local symptoms (haematuria, flank pain, mass)
- Symptoms from venous invasion
- Metastatic symptoms
- Paraneoplastic syndromes
7.2 Symptoms
- This is the most common presentation in the modern era
- Found on USG/CT performed for other indications (e.g., abdominal pain workup, health screening)
- Why? Widespread availability of cross-sectional imaging. These tumours are often small and asymptomatic.
The classic triad is: haematuria + flank pain + palpable renal mass
However, this triad is now rare and when present, usually indicates advanced disease.
| Symptom | Mechanism |
|---|---|
| Haematuria (most common symptom when symptomatic, ~40–60%) | Tumour invades into the collecting system (renal pelvis/calyces), eroding blood vessels → blood enters the urine. Typically painless and intermittent (macro or micro). May cause clot colic if large clots pass through the ureter. |
| Flank pain (~40%) | Due to capsular distension (the renal capsule is innervated by T10–L1 sensory fibres; as tumour grows, it stretches the capsule causing a dull, constant ache). Can also be caused by haemorrhage within the tumour, ureteric obstruction by clots, or direct nerve invasion. |
| Palpable abdominal/flank mass (~25%) | The tumour must be large enough to be palpable — usually > 10 cm. The mass is in the loin, moves with respiration (attached to diaphragm via kidney), is ballottable (bimanually palpable because the kidney is a retroperitoneal organ). |
RCC uniquely invades into the renal vein, IVC, and even the right atrium [4].
| Symptom | Mechanism |
|---|---|
| Left-sided varicocele | Left renal vein invasion → obstructs the left gonadal (testicular) vein which drains into the left renal vein → venous congestion → dilatation of the pampiniform plexus = varicocele [4]. This is classically non-reducible on lying down (unlike idiopathic varicoceles). A new left varicocele in an older man that does NOT decompress when supine should raise alarm for RCC. |
| Bilateral lower limb oedema | IVC invasion/obstruction → impaired venous return from lower limbs → bilateral (symmetric) pitting oedema [4]. Note: unilateral oedema is more suggestive of DVT; bilateral suggests proximal obstruction (IVC). |
| Ascites | IVC obstruction → increased hydrostatic pressure in hepatic veins → transudative ascites (similar mechanism to Budd-Chiari syndrome) [4] |
| Pulmonary embolism | Tumour thrombus in the IVC can fragment and embolise to the pulmonary arteries [4]. This can be the presenting event. |
| Dilated abdominal wall veins (caput medusae-like) | IVC obstruction → blood seeks collateral pathways → superficial abdominal/thoracic veins become dilated |
Left Varicocele — A Classic Exam Trap
A new-onset left varicocele in a man > 40 years that does not decompress on lying flat should prompt investigation for a left renal mass. The reason it's always the LEFT side: the left testicular vein drains into the left renal vein (the right testicular vein drains directly into the IVC, so right-sided RCC less commonly causes varicocele). If you see a right-sided varicocele, think of IVC obstruction or situs inversus.
25% of patients present with advanced locoregional disease or distant metastasis [2].
| Site | Symptoms | Mechanism |
|---|---|---|
| Lung (most common, ~50–60%) | Cough, haemoptysis, dyspnoea, chest pain | Haematogenous spread via renal vein → IVC → right heart → pulmonary arteries. Can present as solitary or multiple pulmonary nodules, or lymphangitis carcinomatosa |
| Bone (~30%) | Bone pain, pathological fractures, spinal cord compression | Haematogenous spread. RCC bony metastases are characteristically lytic (osteoclast-activating) and highly vascular — important because biopsy of bone mets can cause significant haemorrhage. Common sites: spine, pelvis, femur, humerus |
| Brain (~5–10%) | Headache, seizures, focal neurological deficits | Haematogenous spread |
| Liver | RUQ pain, jaundice (late), hepatomegaly | Haematogenous or direct extension (right kidney adjacent to liver) |
| Retroperitoneal lymph nodes | Usually asymptomatic; may cause back pain or ureteric obstruction | Lymphatic drainage |
"Cannonball" lung metastases — RCC is one of the classic causes of multiple, well-defined, round pulmonary nodules on CXR (the others include choriocarcinoma, melanoma, and sarcoma). These are called "cannonball" metastases.
| Symptom | Mechanism |
|---|---|
| Weight loss, anorexia, malaise | Cancer cachexia — tumour produces cytokines (TNF-α, IL-6) that increase basal metabolic rate, suppress appetite, and promote muscle catabolism |
| Fever of unknown origin (FUO) | Tumour produces pyrogens (IL-1, IL-6, TNF-α). RCC is one of the classic causes of FUO of neoplastic origin |
| Night sweats | Same cytokine-mediated mechanism |
7.3 Signs
| Sign | Significance |
|---|---|
| Cachexia | Advanced disease |
| Pallor | Anaemia (chronic disease or haematuria-related) |
| Plethora (ruddy complexion) | Polycythaemia from EPO production (paraneoplastic) |
| Hypertension | Paraneoplastic (renin production) or renal artery compression |
| Sign | Significance |
|---|---|
| Palpable flank/loin mass | Large tumour; ballottable; moves with respiration |
| Hepatomegaly | Liver metastases or Stauffer syndrome (non-metastatic hepatic dysfunction) |
| Ascites | IVC obstruction or peritoneal metastases |
| Sign | Significance |
|---|---|
| Left varicocele (non-reducing on lying flat) | Left renal vein invasion [4] |
| Sign | Significance |
|---|---|
| Bilateral non-pitting → pitting oedema | IVC obstruction |
E. Paraneoplastic Signs (see table in Section 5.3)
Only 20% of renal masses are benign [4]. Key benign mimics:
| Lesion | Features | Key Distinguishing Point |
|---|---|---|
| Oncocytoma | Well-circumscribed, central stellate scar on CT; composed of oncocytes (eosinophilic cells) | Cannot reliably distinguish from chromophobe RCC on imaging alone; often requires histology |
| Angiomyolipoma (AML) | Contains fat, smooth muscle, and blood vessels; strongly associated with tuberous sclerosis | Macroscopic fat on CT (Hounsfield units < -20) is virtually diagnostic; risk of haemorrhage if > 4 cm |
| Simple renal cyst | Bosniak I or II (thin wall, no enhancement, no septation) | Very common, benign, no follow-up needed |
| Complex renal cyst | Bosniak IIF–IV → increasing likelihood of malignancy | Bosniak IV ≈ 100% malignancy rate → requires surgical excision |
High Yield Summary
- RCC arises from renal tubular epithelium (most commonly proximal tubule → clear cell type, 70–80%).
- Epidemiology: Male > Female, 6th–8th decade, median age 64. In HK: incidence 4.8/100,000.
- Major risk factors: Smoking, obesity, hypertension, acquired cystic kidney disease (30× risk in dialysis patients), VHL syndrome, Birt-Hogg-Dubé, hereditary papillary RCC, tuberous sclerosis.
- VHL pathway is central: Loss of VHL → HIF-α accumulation → VEGF (angiogenesis), EPO (polycythaemia), PDGF (proliferation). This explains the tumour's hypervascularity, anti-VEGF therapy responsiveness, and chemo-resistance.
- Most patients are asymptomatic — 50–60% found incidentally on imaging.
- Classic triad (haematuria + flank pain + palpable mass) = late presentation (10–20%).
- RCC uniquely invades the renal vein and IVC → left varicocele (non-reducing), bilateral LL oedema, PE, ascites.
- Paraneoplastic syndromes (6–10%): polycythaemia (EPO), hypercalcaemia (PTHrP), HTN (renin), Stauffer syndrome (non-metastatic hepatic dysfunction → reversible post-nephrectomy), anaemia of chronic disease.
- Most common metastatic sites: Lung (cannonball mets) > bone (lytic, vascular) > liver > brain > lymph nodes.
- Histological subtypes: Clear cell (70–80%) > papillary (10–15%) > chromophobe (5–10%) > collecting duct (~1%) > medullary (< 1%, sickle cell trait).
Active Recall - Renal Cell Carcinoma (Part 1)
[1] Lecture slides: GC 183. Common urological malignancies and their presentations - Nov 7.pdf (pp. 7, 17) [2] Senior notes: felixlai.md (Renal cell carcinoma section) [3] Senior notes: Ryan Ho Urogenital.pdf (p. 145, Section 7.3) [4] Senior notes: maxim.md (Renal cell carcinoma section) [5] Lecture slides: GC 183. Common urological malignancies and their presentations - Nov 7.pdf (p. 17 — RCC Subtypes table)
Differential Diagnosis of a Renal Mass
When you encounter a renal mass — whether discovered incidentally on imaging, found during a haematuria workup, or detected because the patient has flank pain — you must think systematically. Not every renal mass is RCC. The differential is broad, and getting it wrong has major consequences: you don't want to do a radical nephrectomy for a lymphoma (which is treated with chemotherapy) or panic about a simple cyst.
The approach is to ask three sequential questions:
- Is this mass real? (Artefact, normal variant, pseudotumour such as a prominent column of Bertin)
- Is it cystic or solid? (Simple cysts are overwhelmingly benign; solid masses are malignant until proven otherwise)
- If solid or complex cystic — is it benign or malignant?
Differential Diagnoses of Renal Masses — Detailed Breakdown
Only ~20% of renal masses are benign [4]. Key benign differentials:
| Diagnosis | Key Features | Why It Mimics RCC | How to Distinguish |
|---|---|---|---|
| Simple renal cyst | Asymptomatic, ovoid anechoic mass with smooth wall on USG [3] | Very common; large cysts may cause flank mass or pain | Bosniak I–II criteria: thin wall, no septations, no enhancement, no calcification. Requires no follow-up |
| Angiomyolipoma (AML) | Fat attenuation, enhancing without calcification on CT; associated with tuberous sclerosis complex [3] | Can be large, cause pain, and even rupture/haemorrhage (especially if > 4 cm) | Macroscopic fat on CT (Hounsfield units < −20 HU) is virtually diagnostic. Contains fat + smooth muscle + blood vessels ("angio-myo-lipoma" = vessels-muscle-fat). Risk of spontaneous haemorrhage (Wunderlich syndrome) if > 4 cm → embolisation or surgery |
| Oncocytoma | Homogeneous, well-circumscribed solid mass [3]; characteristically has a central stellate scar on CT | Solid, enhancing mass that looks identical to chromophobe RCC on imaging | Cannot reliably distinguish from chromophobe RCC on imaging alone — often requires histological confirmation. Composed of oncocytes (eosinophilic, mitochondria-rich cells). Benign — no metastatic potential |
| Infectious mass (renal abscess, focal pyelonephritis, xanthogranulomatous pyelonephritis) | Often associated with signs/symptoms of UTI and systemic upset [3] | Can appear as an enhancing renal mass with irregular walls | Clinical context: fever, leucocytosis, pyuria, raised CRP/procalcitonin. XGP classically mimics RCC and is only diagnosed post-nephrectomy |
| Renal pseudotumour (hypertrophied column of Bertin, dromedary hump, foetal lobulation) | Normal anatomical variant of renal parenchyma | Can appear as a "mass" on USG | Enhances identically to surrounding normal cortex on CT; no distortion of architecture |
| Complex renal cyst | Cystic lesion with septations, calcifications, or wall thickening | Bosniak III–IV cysts have significant malignancy risk (Bosniak IV ≈ 100%) | Bosniak classification determines management (see below) |
Bosniak Classification of Renal Cysts — Quick Reference
| Category | Features | Malignancy Risk | Management |
|---|---|---|---|
| I | Simple: thin wall, no septa, no calcification, no enhancement | ~0% | No follow-up |
| II | Few thin septa, fine calcification, hyperdense cysts (< 3 cm), no enhancement | ~0% | No follow-up |
| IIF ("F" = follow-up) | More septa, minimally thickened; minimal enhancement; ≥ 3 cm hyperdense cysts | ~5% | Serial imaging |
| III | Thickened irregular walls/septa, measurable enhancement | ~50% | Surgery or biopsy |
| IV | Clearly enhancing soft tissue component | ~100% | Surgery (treat as RCC) |
Xanthogranulomatous Pyelonephritis — The Great Mimicker
XGP is a chronic destructive granulomatous infection (usually from Proteus mirabilis or E. coli with staghorn calculus) that destroys and replaces the renal parenchyma with lipid-laden macrophages. On CT it can look exactly like a locally advanced RCC (irregular mass, perinephric extension). It is often only diagnosed after nephrectomy when the pathologist finds granulomatous tissue instead of carcinoma. Clinical clue: usually occurs in middle-aged women with a history of recurrent UTIs and a non-functioning kidney on the affected side.
| Diagnosis | Key Features | Why It Matters | How to Distinguish from RCC |
|---|---|---|---|
| Urothelial carcinoma of the renal pelvis | Arises from transitional epithelium lining the renal pelvis (~8% of renal malignancies) [2][3] | Treated differently: nephroureterectomy (not radical nephrectomy alone), because the entire urothelial tract is at risk (field change) | Typically presents as a central filling defect in the renal pelvis on CT urogram (not a cortical mass). Often associated with hydronephrosis. Urine cytology may be positive. Risk factors: smoking, aristolochic acid (Chinese herbal nephropathy — important in Hong Kong), analgesic nephropathy |
| Renal metastasis | Usually multiple lesions with borderline enhancement + widespread metastatic disease [3] | Treatment is systemic (chemotherapy/immunotherapy), not surgical — so tissue diagnosis is critical | Common primaries that metastasise to kidney: lung, breast, GIT, prostate, melanoma [2]. Imaging: usually multiple, bilateral, small, minimally enhancing lesions in a patient with known primary cancer. Consider obtaining tissue biopsy if may affect management [3] |
| Lymphoma | Primary renal lymphoma is rare; secondary involvement more common (50% of lymphoma at autopsy have renal involvement) | Treatment is chemotherapy, NOT surgery — this is the critical distinction. Doing a nephrectomy for lymphoma is a disaster | Imaging: multiple bilateral homogeneous masses, or diffuse infiltration causing renomegaly without distortion of the collecting system. Consider obtaining tissue biopsy if may affect management [3]. Look for other evidence of lymphoma (lymphadenopathy, splenomegaly, B symptoms) |
| Wilms' tumour (nephroblastoma) | Most common primary renal malignancy in children (< 15 years; peak age 3) [6] | Presents as an asymptomatic abdominal mass in a child; different staging and treatment protocol from RCC | Age is the key: if a child has a renal mass, think Wilms' first. If an adult has a renal mass, think RCC first. Wilms' rarely crosses the midline (cf. neuroblastoma which does). Associated with WAGR syndrome, Beckwith-Wiedemann syndrome, Denys-Drash syndrome [6] |
| Renal sarcoma | Rare (< 1%); includes leiomyosarcoma, liposarcoma, angiosarcoma | Highly aggressive with poor prognosis | Usually large, heterogeneous mass; tissue diagnosis needed |
| Collecting duct carcinoma | Arises from collecting ducts; rare, aggressive subtype with poor prognosis [5] | Behaves more like urothelial carcinoma than typical RCC; poor response to anti-VEGF therapy | Central (medullary) location rather than cortical; infiltrative pattern on CT |
| Renal medullary carcinoma | Very aggressive, mostly in young patients with sickle cell trait [5] | Nearly universally fatal; presents with metastatic disease | Young patient with sickle cell trait/disease + aggressive renal mass = pathognomonic |
| Condition | Key Features | How to Distinguish |
|---|---|---|
| Renal abscess/perinephric abscess | Fever, leucocytosis, pyuria; history of UTI or haematogenous seeding | CT shows rim-enhancing fluid collection ± gas; responds to antibiotics/drainage |
| Renal infarct | Wedge-shaped non-enhancing area; clinical context of AF, endocarditis, aortic disease | Peripheral, wedge-shaped, does not enhance; cortical rim sign (thin rim of viable subcapsular cortex) |
| Polycystic kidney disease (ADPKD) | Bilateral enlarged kidneys with multiple cysts | Family history, bilateral, large kidneys — but note: RCC can occur within ADPKD kidneys too |
| Haematoma (subcapsular or perirenal) | History of trauma, anticoagulation, or tumour bleed | CT shows high-density non-enhancing collection; may need follow-up to exclude underlying tumour |
| Renal tuberculosis | Chronic destructive granulomatous infection | "Putty kidney" (calcified non-functioning kidney); sterile pyuria; AFB on EMU; history of TB exposure |
Let's think about why we care about the differential:
-
RCC: Treatment is primarily surgical (partial or radical nephrectomy). Anti-VEGF targeted therapy or immunotherapy for metastatic disease. Chemotherapy and radiotherapy are largely ineffective.
-
Urothelial carcinoma of the renal pelvis: Requires nephroureterectomy (removing kidney + entire ureter + bladder cuff) because the entire urothelium is at risk from field cancerisation.
-
Lymphoma / metastasis to kidney: Treatment is systemic (chemotherapy/immunotherapy). Surgery would be inappropriate and harmful. This is why biopsy is indicated when lymphoma or metastasis is suspected [3] — in contrast to typical RCC where biopsy is generally avoided.
-
Angiomyolipoma: Benign. If small and asymptomatic, observation only. If > 4 cm or symptomatic, selective arterial embolisation or nephron-sparing surgery.
-
Oncocytoma: Benign. But since it cannot be reliably distinguished from chromophobe RCC on imaging, it often ends up being resected (and the diagnosis is made post-operatively by the pathologist).
When to Biopsy a Renal Mass
CT-guided core biopsy is traditionally NOT done for suspected RCC due to risk of tumour seeding [3]. Instead, diagnosis is made from the nephrectomy specimen itself (surgery serves as both diagnosis and treatment).
Indications for renal mass biopsy [3]:
- Renal mass of unknown origin (suspicious for metastasis, lymphoma, or non-malignant cause)
- Metastatic disease where the primary is uncertain and systemic therapy is planned
- Patient preference / unfit for surgery — to guide systemic therapy
- Before thermal ablation of a small renal mass
The key principle: you biopsy when the result would change management (e.g., if it's lymphoma → chemo, not surgery).
Differential Diagnosis in Special Populations
- Wilms' tumour (most common — 95% of paediatric renal cancers) [6]
- Neuroblastoma (arises from adrenal/sympathetic chain, can appear as a suprarenal mass — differentiate with urine catecholamines: elevated VMA/HVA in neuroblastoma) [6]
- Mesoblastic nephroma (neonates — benign)
- Clear cell sarcoma of the kidney
- Rhabdoid tumour of the kidney (very aggressive; associated with hypercalcaemia) [6]
| Category | Diagnosis | Key Distinguishing Feature |
|---|---|---|
| Benign | Simple cyst | Anechoic, smooth wall, no enhancement (Bosniak I–II) |
| Angiomyolipoma | Fat on CT (HU < −20); a/w TSC | |
| Oncocytoma | Central stellate scar; cannot distinguish from chromophobe RCC on imaging | |
| Infection (abscess, XGP) | Fever, leucocytosis, UTI history | |
| Pseudotumour | Enhances like normal cortex | |
| Malignant — primary | RCC | Most common; cortical, enhancing, heterogeneous |
| Urothelial CA of renal pelvis | Central filling defect, hydronephrosis, +ve cytology | |
| Wilms' tumour | Children; large smooth mass; WAGR/BWS associations | |
| Collecting duct / medullary CA | Central location; aggressive; sickle cell trait (medullary) | |
| Translocation RCC | Young adults; TFE3/TFEB rearrangement | |
| Renal sarcoma | Rare; large heterogeneous mass | |
| Malignant — secondary | Renal metastasis | Multiple, bilateral, borderline enhancement; known primary [3] |
| Lymphoma | Multiple, bilateral, homogeneous; ± other lymphoma features [3] | |
| Non-neoplastic | Renal infarct | Wedge-shaped; clinical context (AF, endocarditis) |
| Haematoma | High-density non-enhancing; history of trauma/anticoagulation | |
| Renal TB | Calcified "putty kidney"; sterile pyuria; EMU for AFB |
High Yield Summary
- Not all renal masses are RCC — ~20% of renal masses are benign (angiomyolipoma, oncocytoma, simple cysts).
- Key imaging feature for AML: macroscopic fat on CT (HU < −20). Key imaging feature for oncocytoma: central stellate scar — but cannot reliably distinguish from chromophobe RCC without histology.
- Bosniak classification guides management of cystic renal masses: I–II = benign (no follow-up), IIF = follow-up, III = indeterminate (~50% malignant), IV = treat as malignant.
- Urothelial carcinoma of the renal pelvis presents as a central filling defect (not a cortical mass) and requires nephroureterectomy, not nephrectomy alone.
- Lymphoma and renal metastasis are treated with systemic therapy — biopsy is indicated to confirm before committing to chemotherapy.
- CT-guided biopsy is traditionally NOT done for suspected RCC (risk of tumour seeding); it is reserved for when the result would change management (suspected lymphoma, metastasis, or non-malignant cause).
- In children: think Wilms' tumour first; differentiate from neuroblastoma with urine catecholamines (VMA/HVA).
- In young adults with sickle cell trait: think renal medullary carcinoma (very aggressive, nearly universally fatal).
- XGP is the great mimicker of RCC — chronic granulomatous infection that often only gets diagnosed after nephrectomy.
Active Recall - Differential Diagnosis of Renal Masses
References
[2] Senior notes: felixlai.md (Renal cell carcinoma section) [3] Senior notes: Ryan Ho Urogenital.pdf (pp. 145–147, Section 7.3) [4] Senior notes: maxim.md (Renal cell carcinoma section) [5] Lecture slides: GC 183. Common urological malignancies and their presentations - Nov 7.pdf (p. 17 — RCC Subtypes table) [6] Senior notes: felixlai.md (Wilms' tumour section) [7] Senior notes: Ryan Ho Fundamentals.pdf (pp. 340–345, Section 3.5.1 — Haematuria)
Diagnostic Criteria, Diagnostic Algorithm & Investigation Modalities for Renal Cell Carcinoma
Before diving into investigations, let's establish some first principles that make RCC diagnostically unique:
- There is no validated serum tumour marker for RCC — unlike PSA (prostate), AFP/CEA (liver/colon), or CA-125 (ovary). You cannot "screen" with a blood test.
- There is no population-level screening programme for RCC — the only exception is annual USG for patients on long-term dialysis with acquired cystic kidney disease (30× risk) [3].
- Diagnosis is primarily imaging-based — a contrast CT abdomen with characteristic features is usually sufficient to make a clinical diagnosis and proceed directly to surgery.
- The definitive tissue diagnosis comes from the nephrectomy specimen itself — i.e., surgery is both diagnostic and therapeutic simultaneously [2][4].
- CT-guided core biopsy is traditionally NOT done due to risk of tumour seeding [3][4]. Biopsy is reserved for specific situations where the result would change management.
This approach is fundamentally different from, say, breast cancer (where you biopsy first, then operate) or lymphoma (where tissue diagnosis is mandatory before treatment). In RCC, if the imaging is characteristic and the mass is resectable, you skip biopsy and go straight to the operating room.
The pathway differs depending on how the patient presents:
3. Investigation Modalities — Detailed Breakdown
Though not strictly an "investigation," the physical examination provides critical information [2][7]:
| Examination | Finding | Significance |
|---|---|---|
| General | Pallor, cachexia, plethora | Anaemia vs. polycythaemia (paraneoplastic EPO); cachexia = advanced disease |
| Vitals | Hypertension | Paraneoplastic renin production or renal artery compression |
| Abdominal | Palpable abdominal renal mass, ballotable kidneys [2] | Large tumour (usually > 10 cm); firm, smooth, non-tender, moves with respiration |
| Abdominal | Hepatomegaly | Liver metastasis or Stauffer syndrome |
| Scrotal | Scrotal swelling suggesting varicocele [2] | Left varicocele that fails to empty when recumbent = left renal vein invasion |
| Lower limbs | Ankle oedema [2] | IVC thrombosis or venous compression from tumour or lymph node |
There is no single diagnostic blood test for RCC. Bloods serve three purposes: (1) detect paraneoplastic phenomena, (2) assess baseline organ function before surgery, and (3) provide prognostic information.
| Investigation | What to Look For | Clinical Rationale |
|---|---|---|
| CBC with differentials [2] | Anaemia OR erythrocytosis; thrombocytosis | Anaemia = chronic disease (hepcidin-mediated) or haematuria-related iron loss. Erythrocytosis = paraneoplastic EPO production. Thrombocytosis = reactive (IL-6 driven), associated with poorer prognosis |
| Urinalysis [2] | Haematuria (micro or macro) | Tumour invasion into collecting system → RBCs in urine. Non-glomerular pattern (isomorphic RBCs, no casts) |
| Urine cytology [2] | Malignant cells | Sensitivity is low for RCC (better for urothelial carcinoma). Mainly used to exclude concurrent urothelial carcinoma. Positive cytology in a patient with a cortical mass raises the possibility of a concomitant urothelial lesion |
| LFT [2] | Deranged liver function in liver metastasis or Stauffer syndrome | Stauffer syndrome = non-metastatic hepatic dysfunction (raised ALP, GGT, ± bilirubin) without liver mets; reverses post-nephrectomy. If LFTs deranged, you need imaging to differentiate metastatic from paraneoplastic cause |
| Albumin [2] | Low albumin | Nutritional status assessment pre-operatively; hypoalbuminaemia = poor prognosis |
| RFT [2] | Creatinine, eGFR, electrolytes | Baseline renal function should be assessed since patients with preoperative renal dysfunction and those with risk of CKD should be offered partial instead of radical nephrectomy in order to preserve renal function [2]. Also detects hyperkalaemia if obstructive uropathy |
| Serum calcium | Hypercalcaemia | Paraneoplastic: PTHrP production or 1α-hydroxylation of vitamin D [1]. If elevated → check PTH (should be suppressed) and PTHrP |
| Serum LDH [2] | Elevated LDH | May be prognostic in metastatic disease [2] — included in the MSKCC/IMDC prognostic models for metastatic RCC |
| Coagulation profile | PT/INR, APTT | Pre-operative baseline; RCC can cause DIC (rare) or hypercoagulable state |
| ESR/CRP | Elevated | Non-specific; may be raised in paraneoplastic inflammatory response |
Why Check RFT Before Surgery?
This is a crucial pre-operative decision point. If a patient has baseline renal impairment (e.g., solitary kidney, bilateral tumours, CKD), you must preserve as much nephron mass as possible. This is why partial nephrectomy (nephron-sparing surgery) is preferred over radical nephrectomy when technically feasible for T1 tumours — to avoid pushing the patient into dialysis-dependent renal failure. The preoperative eGFR directly influences the surgical plan.
This is where RCC is different from most cancers:
| Method | Details | When Used |
|---|---|---|
| Nephrectomy or partial nephrectomy [2] | Used in most cases to obtain tissue for diagnosis. For patients with isolated solid renal masses, resection with either a partial or complete nephrectomy is preferred to biopsy since it provides both diagnosis and definitive treatment | Standard approach for resectable masses with characteristic imaging |
| Renal mass biopsy (CT or USG guided) [2][3] | Role of percutaneous biopsy is limited; preoperative needle biopsy is usually not used for resectable renal lesions because of low specificity and concern about tumour seeding of the peritoneum [2] | Indications: renal mass of unknown origin suspicious for metastasis, lymphoma, or non-malignant causes; metastatic disease for thermal ablation; patient preference [3] |
| Biopsy of metastatic site [2] | Biopsy of a metastatic lesion is occasionally diagnostic and can be used if there is high index of suspicion for a metastatic lesion to kidney since pathological confirmation is required prior to starting systemic therapy. Biopsy of a metastatic site is often easier and more informative than biopsy of the primary tumour | When systemic therapy is planned and tissue is needed for histological subtyping and molecular profiling |
Common Exam Mistake — Biopsy in RCC
Students frequently state "biopsy the renal mass" as the first diagnostic step. This is WRONG for suspected RCC. Unlike many other cancers, the standard approach is to proceed directly to surgical resection, which simultaneously provides tissue diagnosis and treatment. Biopsy is only indicated when it would change management — e.g., if you suspect lymphoma (treat with chemo, not surgery), metastasis from another primary, or a non-malignant cause like abscess.
3.4 Radiological Investigations
USG is less sensitive than CT in detecting a renal mass but is useful to distinguish a simple benign cyst from a more complex cyst or a solid tumour [2][3].
| Finding | Appearance | Interpretation |
|---|---|---|
| Simple cyst | Round, sharply demarcated with smooth walls; no echoes within the cyst (anechoic); strong posterior wall echo indicating good transmission [2] | Benign (Bosniak I) — no further workup needed |
| Solid mass | Variable echogenicity; hypoechoic halo of tumour pseudocapsule [3] | Suspicious → proceed to contrast CT |
| Cystic cancer | Irregular, thickened walls; complex structure with septa [3] | Suspicious → proceed to contrast CT with Bosniak classification |
| Fat-containing mass | Hyperechoic (bright) | Angiomyolipoma (confirm with CT for macroscopic fat) |
Why USG first?
- Readily available, no radiation, no contrast, cheap, bedside procedure [7]
- Excellent for distinguishing cystic vs. solid — this is its main role
- Can detect hydronephrosis, cortical thinning, renal size
- Limited by operator dependence, body habitus, and inability to assess retroperitoneum well
CT abdomen (renal protocol) with and without contrast is the initial first-line imaging modality for characterising renal masses; it is extremely accurate in staging RCC — 90% accurate [2][3].
Why CT is so good for RCC:
- Provides anatomical detail of the tumour (size, location, relationship to collecting system)
- Shows enhancement pattern (key for distinguishing benign from malignant)
- Evaluates local invasion (perinephric fat, renal vein, IVC)
- Assesses lymph node involvement
- Can image the contralateral kidney (bilateral tumours? solitary kidney?)
- Detects adrenal gland involvement
- One scan stages the tumour (T, N, and partially M)
CT Protocol — Multiphasic Renal CT:
| Phase | Timing | What It Shows | Why It Matters |
|---|---|---|---|
| Non-contrast (plain) | Before contrast | Baseline density (HU); detects calcification, fat, haemorrhage | Macroscopic fat (HU < −20) → AML. Calcification in renal mass → suspicious for malignancy |
| Corticomedullary (arterial) phase | 25–70 sec post-contrast | Cortical enhancement; renal arterial anatomy | Shows tumour vascularity; surgical planning (number of renal arteries, variant anatomy) |
| Nephrographic phase | 80–180 sec post-contrast | Homogeneous renal parenchymal enhancement | Best phase for detecting renal masses — RCC enhances differently from normal parenchyma |
| Excretory (delayed) phase | > 3–5 min post-contrast | Contrast in collecting system | Evaluates relationship of tumour to collecting system; detects urothelial filling defects |
Key CT Findings in RCC:
| Feature | Finding | Interpretation |
|---|---|---|
| Size | 54% RCC if < 1 cm, 78% if 1–3 cm, 80% if 3–4 cm, even higher for larger masses [3] | Probability of malignancy increases with size |
| Enhancement | 20–70 HU on pre-contrast; hyperenhancing ( > 10–15 HU increase) on post-contrast phase [3] | Enhancement = vascular tumour with blood supply → strongly suggestive of malignancy. A simple cyst does NOT enhance |
| Structure | Complex cystic, thickened/irregular walls [3] | Apply Bosniak classification |
| Necrosis | Central low-density (non-enhancing) area | Common in large tumours; reflects outgrowth of blood supply → central ischaemic necrosis |
| Calcification | Mottled, central calcification | 90% specific for malignancy when central/irregular [3] |
| Venous extension | Tumour thrombus in renal vein or IVC (filling defect in contrast-enhanced vein) | T3a (renal vein), T3b (IVC below diaphragm), T3c (IVC above diaphragm) [1] |
| Perinephric fat stranding | Irregular soft tissue density in perirenal fat | T3a if perinephric fat invaded but still within Gerota's |
| Lymphadenopathy | Retroperitoneal nodes > 1 cm short axis | N1 if regional nodes involved |
The remaining 10% inaccuracy on CT is primarily due to failure to detect oncocytoma, which appears identical to RCC on imaging [2].
When CT shows a cystic renal lesion, the Bosniak classification is used to stratify malignancy risk and guide management [2]:
| Category | CT Features | Malignancy Risk | Management |
|---|---|---|---|
| I | Hairline thin wall; density < 20 HU (similar to water); NO septation, calcification or solid components; NO enhancement [2] | ~0% | No follow-up |
| II | Few thin septa (≤ 1 mm); fine calcification; hyperdense cysts < 3 cm; no measurable enhancement | ~0% | No follow-up |
| IIF | More septa; minimally thickened walls; minimal perceived (but not measurable) enhancement; ≥ 3 cm hyperdense cysts | ~5–10% | Serial imaging follow-up |
| III | Thickened irregular walls/septa; measurable enhancement | ~50% | Surgical excision or active surveillance |
| IV | Clearly enhancing soft tissue component adjacent to cystic mass | ~90–100% | Surgical excision (treat as malignant) |
Bosniak Classification — The Key Principle
The whole system revolves around one question: does the cyst wall or its contents enhance after contrast? Enhancement means blood supply. Blood supply means tissue with metabolic activity. Metabolically active tissue in a cyst = likely neoplasm. A perfectly simple cyst has no blood supply (it's just fluid in a balloon), so it should never enhance.
MRI is generally indicated if suspicious of IVC involvement [3].
| Indication | Rationale |
|---|---|
| Suspected IVC tumour thrombus | MRI is superior to CT for delineating the cephalad extent of tumour thrombus in the IVC — i.e., is the thrombus below the hepatic veins? At the level of the hepatic veins? Above the diaphragm? In the right atrium? This determines the surgical approach (abdominal alone vs. thoracoabdominal vs. cardiopulmonary bypass) [2] |
| Contrast allergy or renal impairment | MRI with gadolinium (or non-contrast MRI) avoids iodinated contrast; however, gadolinium carries risk of nephrogenic systemic fibrosis in severe CKD (eGFR < 30) |
| Pregnancy | No ionising radiation |
| Characterisation of indeterminate lesions | MRI can better characterise lesions that are equivocal on CT (e.g., haemorrhagic cysts vs. solid tumours) using T1/T2 signal characteristics and diffusion-weighted imaging |
| Modality | Indication | Findings in Metastatic RCC |
|---|---|---|
| CXR | Baseline; may show cannonball metastases | Multiple well-defined round nodules ("cannonball" mets); solitary pulmonary nodule; pleural effusion; mediastinal lymphadenopathy |
| CT chest | Standard staging investigation for RCC (ESMO/EAU guidelines) [3] | More sensitive than CXR; can detect subcentimetre nodules; lymphangitis carcinomatosis pattern |
| Indication | Finding | Interpretation |
|---|---|---|
| Bone pain, raised serum ALP, or raised calcium | Multiple areas of increased uptake | RCC bony metastases are characteristically lytic — but the bone scan detects the osteoblastic reaction around lytic lesions, so sensitivity is lower than for purely blastic metastases (e.g., prostate). CT or MRI may be more informative |
| Not done routinely if asymptomatic | — | — |
| Indication | Finding |
|---|---|
| Neurological symptoms (headache, seizures, focal deficits) | Ring-enhancing lesions with surrounding vasogenic oedema; often at the grey-white matter junction (haematogenous spread) [8] |
| Not done routinely if asymptomatic | — |
- Not routinely used in the primary workup of RCC
- RCC has variable FDG uptake (clear cell RCC can be FDG-avid or not)
- May be useful for:
- Detecting occult metastases in ambiguous cases
- Monitoring treatment response in metastatic disease
- Differentiating recurrence from post-surgical changes
| Purpose | Investigation | When |
|---|---|---|
| Primary tumour characterisation | CT abdomen and pelvis with contrast (renal protocol) | All patients |
| Local staging (T stage) | CT abdomen ± MRI (for IVC extent) | All patients |
| Nodal staging (N stage) | CT abdomen (retroperitoneal nodes) | All patients |
| Pulmonary metastases (M stage) | CT chest | All patients |
| Bone metastases | Bone scan or CT/MRI | If symptomatic (bone pain, raised ALP, raised Ca) |
| Brain metastases | CT or MRI brain | If neurological symptoms |
| Baseline bloods | CBC, RFT, LFT, Ca, LDH, coagulation | All patients |
| Urinalysis and cytology | Dipstick, microscopy, cytology | If haematuria is the presenting complaint |
The key concept is a two-step process:
Step 1 — Detect and characterise the mass (Is it real? Cystic or solid? Benign or malignant?)
- USG → CT with contrast → apply Bosniak if cystic → assess for fat (AML) → assess enhancement (RCC)
Step 2 — Stage the disease (How far has it spread? What is the treatment plan?)
- CT chest + CT abdomen/pelvis ± MRI (IVC) ± bone scan ± brain imaging
- Baseline bloods for paraneoplastic markers, organ function, and prognosis
Tissue diagnosis comes from the nephrectomy specimen (not pre-operative biopsy) unless biopsy is specifically indicated.
Two widely used prognostic models for metastatic RCC incorporate laboratory values — this is why the blood tests above are so important:
IMDC (International Metastatic RCC Database Consortium) Criteria — "Heng criteria":
| Risk Factor | Threshold | Why |
|---|---|---|
| Karnofsky performance status | < 80% | Functional status predicts survival |
| Time from diagnosis to treatment | < 1 year | Early need for therapy = aggressive biology |
| Haemoglobin | < lower limit of normal | Anaemia = chronic disease / advanced tumour burden |
| Corrected calcium | > upper limit of normal | Paraneoplastic PTHrP = aggressive biology |
| Neutrophil count | > upper limit of normal | Neutrophilia = inflammatory tumour microenvironment |
| Platelet count | > upper limit of normal | Thrombocytosis = IL-6 driven inflammation |
| Risk Group | Number of Factors | Median OS |
|---|---|---|
| Favourable | 0 | ~43 months |
| Intermediate | 1–2 | ~23 months |
| Poor | 3–6 | ~8 months |
The IMDC model guides the choice of first-line systemic therapy in metastatic RCC (immunotherapy-based combinations for intermediate/poor risk; TKI or immunotherapy for favourable risk).
High Yield Summary
- There is no serum tumour marker for RCC — diagnosis is imaging-based.
- CT abdomen with contrast (renal protocol) is the gold standard — 90% accuracy for characterising and staging RCC.
- Enhancement > 10–15 HU on post-contrast CT differentiates solid tumour from simple cyst — this is the single most important imaging feature.
- Bosniak classification stratifies cystic renal lesions: I–II = benign, IIF = follow-up, III–IV = surgical excision.
- MRI is indicated when IVC involvement is suspected — to determine the cephalad extent of tumour thrombus (determines surgical approach).
- Tissue diagnosis comes from the nephrectomy specimen — pre-operative biopsy is NOT standard for resectable masses.
- Biopsy indications: suspected lymphoma, suspected metastasis from another primary, non-malignant differential, before thermal ablation, patient preference.
- Staging workup: CT chest (all patients), bone scan (if symptomatic), brain imaging (if neurological symptoms).
- Baseline bloods serve three functions: detect paraneoplastic syndromes (Ca, Hb, EPO), assess organ function pre-operatively (RFT for surgical planning), and provide prognostic information (IMDC criteria: Hb, Ca, neutrophils, platelets).
- RFT is critical pre-operatively — baseline renal function determines whether partial nephrectomy (nephron-sparing) should be preferred over radical nephrectomy.
Active Recall - Diagnosis and Investigations for RCC
References
[1] Lecture slides: GC 183. Common urological malignancies and their presentations - Nov 7.pdf (pp. 15, 17, 18) [2] Senior notes: felixlai.md (Renal cell carcinoma section — Diagnosis) [3] Senior notes: Ryan Ho Urogenital.pdf (pp. 145–147, Section 7.3) [4] Senior notes: maxim.md (Renal cell carcinoma — Investigations section) [7] Senior notes: Ryan Ho Fundamentals.pdf (pp. 343–345, Section 3.5.1 — Haematuria) [8] Senior notes: Ryan Ho Neurology.pdf (pp. 161, 164 — Brain Metastasis)
Management of Renal Cell Carcinoma — Algorithm, Treatment Modalities, Indications & Contraindications
Before we walk through the algorithm, let's establish the fundamental principles that make RCC management unique among solid cancers:
- Surgery is the main curative treatment for localised RCC — there is no effective adjuvant chemotherapy, but adjuvant pembrolizumab is now recommended for selected high-risk clear-cell RCC after nephrectomy (KEYNOTE-564 criteria) [10][12].
- RCC is classically resistant to conventional chemotherapy — NO role of chemotherapy in treatment of RCC. The reason: the kidney tubular epithelium from which RCC arises is rich in P-glycoprotein (MDR1), a drug efflux pump that actively pumps out chemotherapeutic agents. Additionally, RCC's disordered vasculature (from VEGF overexpression) paradoxically limits effective drug delivery [2].
- Radiotherapy is selective, not routine — stereotactic radiotherapy is used for clinically relevant brain/bone metastases and may be offered as stereotactic ablative radiotherapy (SABR/SBRT) for selected cT1 lesions in patients unfit for surgery [10].
- The immune system matters in RCC — RCC is one of the most "immunogenic" solid tumours. Historically it was one of the few cancers that responded to IL-2 and IFN-α. This immune sensitivity is why modern checkpoint inhibitors (anti-PD-1, anti-CTLA-4) have revolutionised metastatic RCC management.
- The VHL/HIF/VEGF pathway is druggable — loss of VHL → HIF-α accumulation → VEGF overexpression → angiogenesis. This is the rational basis for anti-VEGF TKIs and mTOR inhibitors.
- Even in metastatic disease, surgery often has a role — "cytoreductive nephrectomy" (removing the primary tumour even when metastases are present) and "metastasectomy" (removing isolated metastases) can improve survival in selected patients [3].
3. Management of Localised Disease (Stage I–III)
3.1 Surgical Treatment — The Curative Modalities
"Partial nephrectomy" means removing only the tumour with a margin of normal parenchyma, preserving the rest of the kidney.
Why is this preferred over radical nephrectomy for small tumours?
- Studies show non-inferior overall survival compared to radical nephrectomy for T1 disease [3]
- Better long-term renal function preservation → reduces risk of CKD, cardiovascular morbidity, and metabolic complications (patients who undergo radical nephrectomy lose ~30% of their overall GFR overnight) [3]
- Up to 20% of resected renal masses turn out to be benign (oncocytoma, AML) — so preserving the kidney when possible avoids unnecessary organ loss [3]
| Category | Indication | Rationale |
|---|---|---|
| Absolute | Solitary kidney | No contralateral kidney to compensate — radical nephrectomy would mean dialysis |
| Absolute | Bilateral tumours | Must preserve function on at least one side |
| Absolute | Multiple small tumours | Often hereditary (VHL); will likely develop more tumours → preserve nephron mass |
| Strong relative | Patients with comorbidities that impair renal function or will affect future renal function (e.g., DM, renovascular disease) [2][3] | These patients are already prone to CKD; losing a kidney pushes them toward dialysis |
| Elective | Primary tumour ≤ 7 cm (T1 stage) [1][2] | Standard of care for T1a (≤ 4 cm) and T1b (4–7 cm) when technically feasible |
Contraindications [3]:
- Insufficient volume of remaining parenchyma (tumour too large relative to kidney)
- Renal vein thrombosis (tumour thrombus in the vein makes clamping and partial resection hazardous)
- Unfavourable tumour location (e.g., central tumour adherent to renal vessels or hilum)
- Use of anticoagulants (relative — increases bleeding risk)
| Approach | When Preferred |
|---|---|
| Open | Preferred in difficult cases: solitary kidneys, tumour near the renal hilum [2] |
| Laparoscopic | Technically difficult unless robotic-assisted; comparable outcomes with open approach [2] |
| Robotic-assisted | Increasingly the standard; combines the precision of open surgery with the minimal invasiveness of laparoscopy |
Key operative principle: Should examine kidney carefully to exclude synchronous tumour (7%) [3] — i.e., during partial nephrectomy, the surgeon must check the rest of the kidney for additional tumour foci (especially in hereditary syndromes like VHL).
"Radical nephrectomy" means removing the entire kidney + Gerota's fascia (the fibrous capsule enclosing kidney and perirenal fat) ± related structures.
- Entire kidney
- Gerota's fascia with perirenal fat
- ± Ipsilateral adrenal gland (only if involved — routine adrenalectomy is no longer recommended as there is little risk of adrenal recurrence if not clinically involved) [3]
- ± Regional lymph nodes (extended LN dissection is controversial; usually only in clinically N1 disease or high risk of LN spread) [3]
| Stage | Recommendation |
|---|---|
| T2 (> 7 cm, confined to kidney) | Laparoscopic radical nephrectomy as standard [1][3] — lower morbidity than open, similar oncological outcome |
| T3 (locally advanced) | Open radical nephrectomy as standard [1][3] — allows better access for vascular control, thrombectomy |
| T4 (beyond Gerota's fascia) | Radical nephrectomy ± adrenalectomy [1] |
Key surgical principle: Early ligation of vascular pedicle is important to prevent tumour dissemination; once the artery is occluded, the tumour loses most of its profuse blood supply and massive bleeding during mobilisation becomes less likely [2][3].
Why early ligation? RCC is one of the most vascular solid tumours (remember: VHL loss → VEGF overexpression → abundant tumour vasculature). If you start mobilising the kidney before controlling the artery, you risk catastrophic haemorrhage AND tumour cell dissemination via disturbed venous outflow.
| Procedure | Indication | Details |
|---|---|---|
| Venous thrombectomy [1][3] | T3 disease with renal vein/IVC extension | Simple thrombectomy if thrombus extends up to major hepatic veins; cardiopulmonary bypass ± hypothermic circulatory arrest if thrombus extends above hepatic veins [2][3] |
| Ipsilateral adrenalectomy | Only if adrenal involvement on imaging/intraoperatively | Not routinely performed — little risk of adrenal recurrence if not clinically involved [3] |
| Extended LN dissection | Clinically N1 or high risk of LN spread [3] | Controversial; staging rather than therapeutic benefit in most cases |
Thrombectomy Complexity — From the Renal Vein to the Right Atrium
The surgical approach to tumour thrombus depends entirely on its cephalad extent, which is why MRI is so important preoperatively:
| Thrombus Level | Surgical Approach |
|---|---|
| Renal vein only | Standard radical nephrectomy with venous clamping |
| IVC below hepatic veins | Abdominal approach; IVC clamping above and below thrombus |
| IVC at/above hepatic veins | May need liver mobilisation, Pringle manoeuvre |
| Above diaphragm / right atrium | Cardiopulmonary bypass ± hypothermic circulatory arrest [2][3] — a combined cardiothoracic + urological procedure |
This escalating complexity is why accurate preoperative staging with MRI is essential — it determines whether you need a urologist alone, or a urologist + hepatobiliary surgeon + cardiac surgeon in the same operating room.
| Timing | Complication | Mechanism |
|---|---|---|
| Operative | Mortality (~2%) | Anaesthetic risk, haemorrhage |
| GA complications | Standard anaesthetic risks | |
| Pneumothorax | Pleural injury (especially with flank/posterior approach to upper pole tumours) | |
| Injury to neighbouring organs (GI tract, major blood vessels, spleen, pancreas) | Anatomical proximity | |
| Post-operative | Temporary or permanent renal failure | Loss of functioning nephrons; especially if pre-existing CKD or solitary kidney |
| Ileus | Retroperitoneal dissection → sympathetic irritation → paralytic ileus | |
| Wound infection (superficial and deep) | Standard surgical complication |
3.2 Non-Surgical Local Treatments
| Aspect | Details |
|---|---|
| Principle | Destroy tumour tissue in situ using extreme heat (RFA, microwave) or cold (cryoablation), without removing the kidney |
| Indications | Small cortical tumours (≤ 3 cm), especially for frail patients, high surgical risk, solitary kidney, compromised renal function, hereditary or multiple bilateral tumours [3] |
| Approach | Percutaneous (image-guided) or laparoscopic |
| Pre-procedure | Percutaneous renal biopsy should be done to confirm diagnosis [3] — unlike nephrectomy, you won't have a surgical specimen, so you need tissue proof before ablating |
| Outcomes | Short- and long-term outcomes can be comparable with PN/RN for small tumours [3]; however oncological outcomes are inferior to surgery and associated with a higher recurrence rate overall [2] |
| Advantage | Maximal preservation of renal parenchyma and function [2] |
Why biopsy before ablation? Because with surgery, the removed specimen provides tissue diagnosis. With ablation, nothing is removed — you're destroying the tumour in place. You need to confirm it's actually cancer (and not an oncocytoma or AML) before you ablate it.
| Aspect | Details |
|---|---|
| Rationale | Improved imaging modalities led to increased detection of small renal masses, of which many are slow-growing [3] |
| Indication | Elderly patients with significant comorbidities or short life-expectancy + tumour < 4 cm [3] |
| Protocol | Serial imaging (CT or USG) at regular intervals; intervene if growth > 3–4 mm/year or > 4 cm |
| Biopsy | Consider renal mass biopsy if the result would change counselling or treatment; biopsy is mandatory before thermal ablation because there will be no surgical specimen [10] |
| Outcome | Slow growth in most cases (mean 3 mm/year); progression to metastatic disease only in 1–2% [3] |
Why is this safe? Small renal masses (< 4 cm, T1a) have a very low rate of metastasis. In elderly patients with competing comorbidities (heart failure, COPD, etc.), the risk of dying FROM the kidney cancer is lower than the risk of dying WITH it from something else. Surgery carries operative risks that may outweigh the oncological benefit.
SABR/SBRT is no longer just "palliation" in RCC. It may be offered to patients with cT1 renal tumours who have an indication for treatment but are unfit for surgery. Evidence is still less mature than for surgery, so patients should be counselled about uncertainty in long-term oncological outcomes.
NO role of adjuvant chemotherapy following complete resection of localised RCC [2].
Current guidelines separate chemotherapy/targeted therapy from adjuvant PD-1 therapy:
- Adjuvant chemotherapy — no benefit (RCC is chemo-resistant)
- Adjuvant targeted therapy (sunitinib, sorafenib, pazopanib, everolimus, axitinib) — not recommended after nephrectomy because OS benefit has not been shown and toxicity is significant [10].
- Adjuvant pembrolizumab — offer to selected clear-cell RCC patients, preferably within 12–16 weeks post-nephrectomy after restaging, if they match KEYNOTE-564 recurrence-risk groups: pT2 grade 4 or sarcomatoid, pT3 any grade, pT4, pN+, or M1 no evidence of disease after complete metastasectomy within one year [10][12].
- Other adjuvant/perioperative ICI strategies — atezolizumab, nivolumab, nivolumab + ipilimumab, and perioperative nivolumab have not shown consistent benefit and should not be treated as equivalent to pembrolizumab [10].
For lower-risk resected RCC, the standard remains surveillance. For high-risk clear-cell RCC, use shared decision-making because pembrolizumab reduces recurrence risk but can cause immune-related toxicity and overtreatment [10].
4. Management of Metastatic Disease (Stage IV)
This is where RCC management has been transformed over the past two decades. Let's build up the logic from first principles.
Before choosing systemic therapy, you must stratify the patient's prognosis. The IMDC (International Metastatic RCC Database Consortium) criteria — also called "Heng criteria" — determine the treatment approach:
| Risk Factor | Threshold |
|---|---|
| Karnofsky performance status | < 80% |
| Time from diagnosis to systemic treatment | < 1 year |
| Haemoglobin | < lower limit of normal |
| Corrected calcium | > upper limit of normal |
| Neutrophil count | > upper limit of normal |
| Platelet count | > upper limit of normal |
| Risk Group | Number of Factors | Implication |
|---|---|---|
| Favourable | 0 | Indolent biology; consider TKI monotherapy or IO-TKI |
| Intermediate | 1–2 | Standard biology; combination immunotherapy preferred |
| Poor | 3–6 | Aggressive biology; combination immunotherapy preferred |
4.2 Local Therapy in Metastatic Disease
Even in metastatic disease, surgery can play a role. This is unusual for most solid cancers.
| Aspect | Details |
|---|---|
| Definition | Removal of the primary kidney tumour in the setting of metastatic disease — not curative unless all disease can be cleared |
| Indication | Good performance status with no immediate need for systemic therapy, symptomatic primary tumour, or oligometastatic disease where complete local treatment of metastases is achievable [10] |
| Rationale | Can reduce tumour burden and delay systemic therapy in highly selected patients; complete resection of primary + oligometastases may be potentially disease-controlling |
| Contraindication | IMDC/MSKCC poor risk, high metastatic volume, rapidly progressive disease, poor performance status, or asymptomatic synchronous primary tumour that requires immediate systemic therapy |
| Evidence | CARMENA showed sunitinib alone was non-inferior to immediate cytoreductive nephrectomy + sunitinib in intermediate/poor-risk patients. Current guidance favours upfront IO-based systemic therapy for intermediate/poor-risk patients who need treatment, with delayed CN considered only if they derive clinical benefit [10] |
| Aspect | Details |
|---|---|
| Definition | Surgical removal of isolated metastatic deposits |
| Indication | Favourable-risk patients where complete resection is possible; oligometastatic disease [3] |
| Examples | Pulmonary metastasectomy (lung mets are the most common and most amenable to resection); resection of solitary brain met; bone tumour resection for impending fracture |
| Alternatives | Stereotactic radiotherapy (SRS/SBRT), surgical removal [3] |
| Adjuvant after metastasectomy | NOT needed [3] |
| Outcome | Increased overall and cancer-specific survival in selected patients [3] |
Why Can You Resect Lung Metastases in RCC?
This seems counterintuitive — if cancer has already spread, why does removing metastases help? The answer lies in RCC's biology:
- RCC metastases can grow slowly (especially in favourable-risk patients)
- RCC is chemo-resistant, so you can't rely on systemic therapy to eliminate residual disease
- In oligometastatic disease (few, resectable metastases), complete surgical clearance can result in durable remission
- Metastasectomy may have a role in selected cases (e.g., RCC, CA colon) [9] — lung metastasectomy criteria: surgically resectable, adequate cardiopulmonary reserve, primary tumour controllable
This is different from, say, pancreatic cancer with liver metastases — where the biology is so aggressive that removing metastases provides no benefit because new ones appear immediately.
4.3 Systemic Therapy for Metastatic RCC
Why is RCC responsive to immunotherapy? RCC is one of the most immunogenic solid tumours. Evidence:
- Spontaneous regression of metastases after nephrectomy (rare but well-documented)
- Historical responses to IL-2 and IFN-α
- High tumour mutational burden in many cases → more neoantigens → more immune targets
- Rich immune cell infiltrate in tumour microenvironment
| Agent | Class | Mechanism | Notes |
|---|---|---|---|
| Nivolumab | Anti-PD-1 [1][2][3] | PD-1 is a "brake" on T cells. Tumours express PD-L1 which binds PD-1 on T cells, telling them to "stand down." Nivolumab blocks this interaction → T cells remain activated → attack tumour | Can be used as monotherapy (2nd line) or in combination |
| Ipilimumab | Anti-CTLA-4 [1][3] | CTLA-4 is another immune checkpoint on T cells that suppresses activation. Blocking it → enhanced T cell priming and proliferation | Used in combination with nivolumab |
| Pembrolizumab | Anti-PD-1 [1] | Same mechanism as nivolumab | Used in combination with axitinib or lenvatinib |
| High-dose IL-2 [2][3] | Cytokine therapy | Directly stimulates T cell proliferation and activation | Effective with long-term remissions without relapse in a minority; associated with high toxicity often not tolerable [2]. Largely superseded |
| IFN-α [2][3] | Cytokine therapy | Enhances immune recognition of tumour cells; anti-proliferative | Combined with cytoreductive nephrectomy can improve survival [2]; largely superseded by checkpoint inhibitors [3] |
Current first-line regimens (2024–2026 guidelines):
| IMDC Risk | First-Line Regimen | Rationale |
|---|---|---|
| Favourable (0 RF) | Pembrolizumab + axitinib, lenvatinib + pembrolizumab, nivolumab + cabozantinib, nivolumab + ipilimumab, or sunitinib/pazopanib [10][11] | IO-TKI combinations improve PFS/response; OS advantage over sunitinib is less clear in favourable-risk disease, so TKI monotherapy remains acceptable when appropriate |
| Intermediate/Poor (≥ 1 RF) | Nivolumab + ipilimumab, pembrolizumab + axitinib, lenvatinib + pembrolizumab, or nivolumab + cabozantinib [10][11][12] | IO-based combinations are standard; VEGFR-TKI monotherapy is reserved for patients who cannot receive or tolerate immune checkpoint inhibition |
Second-line and beyond:
| Line | Options |
|---|---|
| After IO-based first-line | Cabozantinib or another VEGF-TKI [10] |
| After VEGF-TKI monotherapy first-line | Nivolumab or cabozantinib [10] |
| Later lines | Sequence an active agent not previously used; belzutifan is an alternative to everolimus after second- to fourth-line therapy for clear-cell metastatic RCC [10] |
These drugs target the VHL/HIF/VEGF axis and the mTOR pathway:
| Class | Examples | Mechanism | Key Points |
|---|---|---|---|
| Tyrosine kinase inhibitors (TKIs) | Sunitinib, pazopanib, axitinib, sorafenib, cabozantinib, lenvatinib, tivozanib [1][2][3][10] | Block VEGF receptor (and other kinases) → inhibit tumour angiogenesis and proliferation. Since RCC is VEGF-driven (VHL loss → HIF → VEGF), cutting off the blood supply starves the tumour | Single-agent VEGF-TKI first-line therapy has largely been superseded by IO-based combinations, except in favourable-risk disease or when ICI cannot be used. Cabozantinib has the strongest later-line data after IO-based therapy [10] |
| Anti-VEGF monoclonal antibody | Bevacizumab [1][2] | "Bevacizumab" → "beva" (from "beverage"? No — named by Genentech). It's a humanised monoclonal antibody that binds circulating VEGF → prevents VEGF from binding its receptor → anti-angiogenic | Usually combined with IFN-α; less commonly used now with the advent of IO combinations |
| mTOR inhibitors | Temsirolimus, everolimus [2][3] | mTOR (mechanistic target of rapamycin) is a kinase in the PI3K/AKT/mTOR pathway that promotes cell growth and proliferation. In RCC, this pathway is often upregulated. Inhibiting mTOR → reduces cell growth, angiogenesis, and metabolism | Their front-line role has been superseded. Everolimus may be used later line, but belzutifan and VEGF-targeted options are often preferred when available [10] |
| HIF-2α inhibitor | Belzutifan [10] | Blocks HIF-2α transcriptional signalling downstream of VHL loss | Later-line option for previously treated clear-cell metastatic RCC; also relevant in VHL-associated disease |
Drug name breakdown:
- "Suni-tinib" → "-tinib" = tyrosine kinase inhibitor
- "Pazo-panib" → "-panib" = pan (many) kinase inhibitor
- "Bevaci-zumab" → "-zumab" = humanised monoclonal antibody
- "Nivo-lumab" → "-lumab" = fully human monoclonal antibody
- "Tems-iro-limus" → "-limus" = mTOR inhibitor (from rapamycin/sirolimus)
| Subtype | Recommended Approach |
|---|---|
| Papillary RCC | Cabozantinib has randomised phase II evidence over sunitinib; lenvatinib + pembrolizumab or nivolumab + cabozantinib are options based on smaller studies [10] |
| Other non-ccRCC | Sunitinib, lenvatinib + pembrolizumab, nivolumab + ipilimumab, or cabozantinib + nivolumab (except chromophobe RCC for the latter) may be offered, recognising weaker evidence [10] |
| Collecting duct / medullary carcinoma | May respond better to platinum-based chemotherapy (behaves more like urothelial carcinoma); renal medullary carcinoma is an exception where cytotoxic combinations remain important [10] |
| Sarcomatoid differentiation | Treat as high-priority for immune checkpoint combination therapy |
| Modality | Role in RCC |
|---|---|
| Chemotherapy | NO role for typical clear-cell metastatic RCC due to low response rate and short-lived responses [2][10]. Exceptions include collecting duct and medullary carcinoma, where platinum-based cytotoxic regimens may be used [10] |
| Radiotherapy | Not routine adjuvant therapy after nephrectomy, but stereotactic radiotherapy is used for brain/bone metastases for local control and symptom relief. SABR/SBRT can be considered for selected cT1 renal tumours when patients are unfit for surgery [10] |
| Stage | T Classification | Standard Treatment | Alternatives |
|---|---|---|---|
| T1 (≤ 7 cm) | T1a ≤ 4 cm; T1b 4–7 cm | Partial nephrectomy [1] | Cryotherapy/RFA; SABR/SBRT; active surveillance or watchful waiting for selected frail/comorbid patients [10] |
| T2 (> 7 cm, confined) | T2a 7–10 cm; T2b > 10 cm | Laparoscopic/open radical nephrectomy [1] | — |
| T3 (locally advanced) | Renal vein/IVC/perinephric invasion | Radical nephrectomy + thrombectomy [1] | ± LN dissection if N+ |
| T4 (beyond Gerota's) | Including ipsilateral adrenal | Radical nephrectomy ± adrenalectomy [1] | — |
| Metastatic (M1) | Any T, any N | IO-based systemic therapy for most clear-cell RCC, based on IMDC risk and patient factors [10][11][12] | ± delayed cytoreductive nephrectomy; ± metastasectomy/SBRT for selected oligometastatic disease |
After curative-intent surgery, patients need follow-up to detect recurrence:
| Risk Level | Surveillance Protocol |
|---|---|
| High-risk (T3–T4, N+, high grade) | CT every 3–6 months for 2 years, then annually [3] |
| Low-risk (T1–T2, N0, low grade) | CT annually [3] |
What are you looking for?
- Local recurrence in the renal fossa
- Contralateral kidney tumour (metachronous)
- Distant metastases (lung, bone, liver, brain)
- Decline in renal function (especially post-radical nephrectomy)
High Yield Summary
- Surgery is the only cure for localised RCC. Partial nephrectomy is standard for T1 (≤ 7 cm); radical nephrectomy for T2 and above [1].
- Absolute indications for partial nephrectomy: solitary kidney, bilateral tumours, multiple small tumours [2].
- Early ligation of the vascular pedicle during radical nephrectomy is crucial to prevent haemorrhage and tumour dissemination [2][3].
- IVC tumour thrombus above hepatic veins requires cardiopulmonary bypass ± hypothermic circulatory arrest [2][3].
- NO role for adjuvant chemotherapy after complete resection of localised RCC [2][3]. Adjuvant pembrolizumab is now offered to selected high-risk clear-cell RCC patients after nephrectomy using KEYNOTE-564 criteria [10][12].
- Chemotherapy has NO role in RCC (P-glycoprotein efflux pump; chemo-resistant) [2].
- Radiotherapy is selective: stereotactic RT for brain/bone metastases and SABR/SBRT for selected cT1 patients unfit for surgery [10].
- Metastatic RCC management is guided by IMDC risk stratification [3]:
- Favourable: IO-TKI, nivolumab + ipilimumab, or TKI monotherapy depending on patient factors
- Intermediate/poor: IO-based combination therapy (nivolumab + ipilimumab, pembrolizumab + axitinib, lenvatinib + pembrolizumab, or nivolumab + cabozantinib)
- Cytoreductive nephrectomy is not routine upfront therapy for intermediate/poor-risk patients needing systemic treatment; consider immediate CN only in selected patients or delayed CN after response [10].
- Metastasectomy improves survival in selected patients with oligometastatic, resectable disease [3].
- Active surveillance is safe for elderly/frail patients with tumours < 4 cm (mean growth 3 mm/year, 1–2% metastatic progression) [3].
- Biopsy before thermal ablative therapy (RFA/cryo) is mandatory since no surgical specimen will be available [3][10].
Active Recall - Management of RCC
References
[1] Lecture slides: GC 183. Common urological malignancies and their presentations - Nov 7.pdf (p. 19 — RCC Treatment) [2] Senior notes: felixlai.md (Renal cell carcinoma — Treatment section) [3] Senior notes: Ryan Ho Urogenital.pdf (pp. 148–149, Section 7.3.1 — Management) [7] Senior notes: Ryan Ho Fundamentals.pdf (p. 345 — Management of urinary tumours) [8] Senior notes: Ryan Ho Neurology.pdf (pp. 164–165 — Brain metastasis management) [9] Senior notes: Ryan Ho Respiratory.pdf (p. 150 — Secondary tumours of the lungs) [10] European Association of Urology (EAU) Guidelines on Renal Cell Carcinoma, 2026 update. [11] NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer, Version 1.2026. [12] ASCO Guideline: Management of Metastatic Clear Cell Renal Cell Carcinoma, published 2023, reviewed/updated 2026.
Complications of Renal Cell Carcinoma
Complications of RCC can be divided into three broad categories: (A) complications of the disease itself (untreated or progressive), (B) complications of surgical treatment, and (C) complications of systemic therapy. Let's work through each systematically, always connecting back to the underlying mechanism.
1. Complications of the Disease Itself
These are the consequences of the tumour growing, invading, metastasising, and secreting bioactive substances. Many of these overlap with the clinical features discussed earlier, but here we frame them as complications — i.e., things that cause morbidity and mortality.
| Complication | Mechanism | Clinical Consequence |
|---|---|---|
| Ureteric/pelvicalyceal obstruction | Tumour mass compresses or invades the renal pelvis or ureter → blocks urine drainage | Hydronephrosis → renal function decline on ipsilateral side; if bilateral (rare) or solitary kidney → obstructive renal failure. May present as flank pain |
| Haemorrhage (spontaneous tumour bleed) | RCC is one of the most vascular tumours (VHL loss → VEGF → abundant neovascularisation). Tumour vessels are fragile and lack normal smooth muscle → prone to spontaneous rupture | Retroperitoneal haemorrhage (Wunderlich syndrome — though more classically associated with AML, RCC can also cause it); gross haematuria with clot retention; haemorrhagic shock (rare) |
| Direct invasion into adjacent organs | T4 disease — tumour invades beyond Gerota's fascia | Invasion into adrenal gland, liver (right-sided), spleen/pancreas tail (left-sided), diaphragm, psoas muscle, bowel |
This is the hallmark complication unique to RCC — the propensity to grow into the venous system as a tumour thrombus.
| Complication | Mechanism | Clinical Consequence |
|---|---|---|
| Left varicocele [1] | Left renal vein invasion → obstructs left gonadal vein outflow | Non-reducible left scrotal swelling; infertility (secondary to heat from varicocele) |
| Lower limb oedema [1] | IVC tumour thrombus → obstructed venous return from lower limbs | Bilateral leg swelling, may be massive |
| Ascites | IVC obstruction → hepatic vein congestion → Budd-Chiari-like picture → transudative ascites | Abdominal distension, shifting dullness |
| Pulmonary embolism [1] | Tumour thrombus fragments can detach and embolise to the pulmonary arteries — just like a DVT/PE but the "clot" is actually tumour | Sudden dyspnoea, pleuritic chest pain, haemoptysis, cardiovascular collapse. Can be the presenting event and can be fatal |
| Hepatic venous congestion / Budd-Chiari syndrome | IVC tumour thrombus at or above the level of the hepatic veins → hepatic venous outflow obstruction | Hepatomegaly, RUQ pain, ascites, elevated LFTs, portal hypertension |
25% of patients have advanced locoregional disease or distant metastasis at presentation [2]. The complications depend on the site of metastasis:
| Site | Complication | Mechanism | Management |
|---|---|---|---|
| Lung (most common) [2] | Respiratory failure, haemoptysis, pleural effusion, airway obstruction | Tumour replaces normal lung parenchyma; erosion into bronchial vasculature; lymphangitis carcinomatosis → severe dyspnoea [9] | Systemic therapy; palliative radiotherapy; pleurodesis for effusions; metastasectomy if oligometastatic [9] |
| Bone [2] | Pathological fractures, spinal cord compression, hypercalcaemia, bone pain | RCC bone metastases are characteristically lytic (osteoclast-activating) and highly vascular — biopsy or even minor trauma can cause significant haemorrhage. Lytic destruction weakens the bone cortex → fracture with minimal force | Bisphosphonates/denosumab (inhibit osteoclast activity); orthopaedic stabilisation; palliative radiotherapy; decompressive surgery for cord compression |
| Brain [8] | Seizures, focal neurological deficits, raised ICP, cognitive dysfunction | Haematogenous spread → usually at grey-white junction (watershed areas where vessel calibre decreases, trapping tumour emboli) [8]. Surrounding vasogenic oedema causes mass effect | Dexamethasone (reduce oedema); AEDs if seizures; SRS/surgery for solitary operable lesions; WBRT for multiple lesions [8] |
| Liver [2] | Hepatic failure (late), RUQ pain, jaundice | Direct extension (right kidney) or haematogenous spread | Systemic therapy; rarely hepatic resection |
| Adrenal | Usually asymptomatic; rarely adrenal insufficiency | Contralateral adrenal metastasis (ipsilateral is by direct invasion = T4) | Systemic therapy; adrenalectomy if isolated |
| Choroid (eye) [10] | Visual loss, visual field defects | Haematogenous spread to the highly vascular choroid | Plaque radiotherapy or EBRT [10] |
Bone Metastases in RCC — A Haemorrhagic Hazard
RCC bone metastases are uniquely hypervascular (remember: the tumour is pumping out VEGF). This means that biopsy of a suspected RCC bone metastasis can cause life-threatening haemorrhage. If a patient with a known renal mass has a lytic bone lesion, do NOT blindly biopsy it without considering pre-operative embolisation or at least being prepared for significant bleeding. Orthopaedic surgeons should be warned.
These affect 6–10% of RCC patients and can cause significant morbidity even without metastatic disease [4]:
| Paraneoplastic Syndrome | Mechanism | Complication if Untreated |
|---|---|---|
| Hypercalcaemia [1][11] | Most common paraneoplastic syndrome in RCC; caused by tumour secretion of PTHrP [1]; also possible via 1α-hydroxylation of vitamin D by tumour cells, or lytic bone metastases [11] | Confusion, polyuria, polydipsia, dehydration, constipation, cardiac arrhythmias (shortened QT), renal stones, and in severe cases coma and death. Management: IV NS (rehydration) → bisphosphonate (pamidronate/zoledronic acid) ± calcitonin [11] |
| Polycythaemia [1] | Ectopic production of erythropoietin [1] (HIF-α drives EPO transcription in VHL-deficient tumour cells) | Hyperviscosity syndrome → thrombosis (DVT, PE, stroke), headache, plethora, visual disturbance. Management: phlebotomy; definitive = treat the tumour |
| Hypertension [1] | Ectopic renin secretion [1] → RAAS activation → Na/water retention + vasoconstriction | Accelerated/malignant hypertension → end-organ damage (LVH, renal impairment, retinopathy, stroke). Management: antihypertensives; definitive = tumour resection |
| Fever, weight loss, and cachexia [1] | Cytokine-mediated [1] (IL-6, TNF-α, IL-1) → increased BMR, muscle catabolism, anorexia | Progressive debilitation; may mimic infection (FUO workup). RCC is a classic cause of PUO/FUO of neoplastic origin |
| Stauffer syndrome (nonmetastatic hepatic dysfunction) [1] | Unknown exact mechanism — likely IL-6-mediated hepatocyte dysfunction | Deranged LFTs (raised ALP, GGT, ± bilirubin), hepatosplenomegaly, fever — all without liver metastases. Resolves after nephrectomy. If LFTs don't normalise → suspect recurrence or true metastatic disease |
| Anaemia of chronic disease | Hepcidin upregulation (IL-6 → hepatic hepcidin production → blocks iron export from macrophages → functional iron deficiency) | Fatigue, dyspnoea, reduced exercise tolerance. Iron studies: low serum iron, low TIBC, high ferritin |
| AA amyloidosis | Chronic inflammation → sustained serum amyloid A (SAA) production → amyloid fibril deposition in kidneys, liver, spleen | Nephrotic syndrome (proteinuria), hepatosplenomegaly, GI dysfunction. Rare but important |
| Thrombocytosis | Reactive — IL-6-driven hepatic thrombopoietin production | May contribute to hypercoagulable state; associated with poorer prognosis |
2. Complications of Surgical Treatment
The lecture slides specifically highlight complications of partial nephrectomy and radical nephrectomy [1].
| Complication | Mechanism | Details |
|---|---|---|
| General anaesthetic risk [2] | Standard GA risks | Aspiration pneumonia, atelectasis, cardiovascular events |
| Bleeding [2] | RCC is highly vascular; renal hilum contains large-calibre vessels | Intraoperative haemorrhage; post-operative haematoma. Early ligation of renal artery mitigates this risk |
| Superficial or deep wound infections [2][3] | Standard surgical complication | More common in open approach; risk increased by obesity, DM, immunosuppression |
| Paralytic ileus [2] | Retroperitoneal dissection → irritation of sympathetic plexus → temporary bowel dysmotility; especially for the transperitoneal approach; ileus is not common when peritoneal cavity is not entered [2] | Abdominal distension, nausea, absent bowel sounds. Usually self-limiting |
| Pneumothorax [2][3] | Pleural injury — especially when operating on upper pole tumours via a flank approach, the pleura may be inadvertently entered | Post-op respiratory distress; diagnosed on CXR; managed with chest drain |
| Injury to adjacent organs [2][3][4] | Anatomical proximity during dissection | Left kidney: spleen, pancreas (tail). Right kidney: liver, gallbladder, duodenum (D2) [2][4] |
| Mortality | ~2% [3] | Higher in T3–T4 disease with IVC involvement requiring complex reconstruction |
| Complication | Mechanism | Details |
|---|---|---|
| Bleeding from the resection bed [4] | The cut surface of the remaining kidney is raw and vascular; warm ischaemia time during clamping must be < 30 minutes to avoid ischaemic damage, but this limits haemostasis time | May require re-exploration; use of haemostatic agents (Surgicel, TachoSil) |
| Urine leakage [4] | If the resection margin enters the collecting system and the defect is not adequately repaired | Urinoma formation; may require ureteric stenting or percutaneous drainage |
| Recurrence in the ipsilateral kidney [4] | Positive surgical margin; satellite tumour foci missed at initial surgery (7% synchronous tumours) [3] | Requires surveillance; may need completion nephrectomy |
| Warm ischaemia injury | Renal artery clamping during partial nephrectomy causes temporary ischaemia → if prolonged ( > 25–30 min), risk of irreversible tubular necrosis | Transient or permanent decline in ipsilateral kidney function; mitigated by selective arterial clamping, early unclamping, or cold ischaemia techniques (ice/cold fluid) [4] |
| Complication | Mechanism | Details |
|---|---|---|
| Temporary or permanent renal failure [2][3] | Loss of entire kidney reduces total nephron mass by ~50%; if pre-existing CKD or solitary kidney → high risk of dialysis dependence | This is THE major long-term complication and the reason why partial nephrectomy is preferred for T1 tumours. Post-RN patients have increased long-term risk of CKD stage ≥ 3, cardiovascular disease, and all-cause mortality |
| Long-term metabolic/cardiovascular consequences | Reduced renal function → hypertension, accelerated atherosclerosis, metabolic syndrome | Lifelong monitoring of RFT; cardiovascular risk factor management |
Why Partial Nephrectomy Protects Against CKD
The kidney has limited regenerative capacity. After radical nephrectomy, the contralateral kidney undergoes compensatory hypertrophy (individual nephrons enlarge and increase GFR), but this compensation is incomplete and plateaus. The remaining kidney handles 60–70% of the original total GFR. However, any future insult (diabetes, hypertension, contrast nephropathy, NSAID use) now acts on a single kidney with reduced reserve. This is why partial nephrectomy preserves kidney function better → limits development of long-term metabolic/CVS disorders [3].
3. Complications of Systemic Therapy
Modern metastatic RCC treatment involves checkpoint inhibitors and TKIs, both of which have significant toxicity profiles.
The key concept: checkpoint inhibitors work by releasing the brakes on the immune system. The downside is that the activated immune system can attack normal tissues → immune-related adverse events (irAEs).
| Organ System | irAE | Mechanism | Management |
|---|---|---|---|
| Skin | Rash, pruritus, vitiligo | T-cell-mediated attack on melanocytes and keratinocytes | Topical steroids; systemic steroids if severe |
| GI | Colitis, diarrhoea (especially with anti-CTLA-4 agents like ipilimumab) | Immune-mediated inflammation of colonic mucosa | Hold drug; IV steroids; infliximab if refractory |
| Liver | Hepatitis (raised transaminases) | Immune-mediated hepatocyte destruction | Hold drug; steroids; mycophenolate if refractory |
| Endocrine | Thyroiditis (hypo > hyperthyroid), hypophysitis, adrenal insufficiency, type 1 DM | Immune destruction of endocrine glands | Hormone replacement (often permanent); steroids for hypophysitis |
| Lung | Pneumonitis | Immune-mediated alveolar inflammation | Hold drug; high-dose steroids; may be fatal if not recognised early |
| Renal | Interstitial nephritis | Immune-mediated tubulointerstitial inflammation | Hold drug; steroids |
| Neurological | Neuropathy, myasthenia-like syndrome, encephalitis | Autoimmune attack on peripheral/central nervous system | Hold drug; steroids; IVIG/plasmapheresis |
irAEs — The Rule of Thumb
Anti-CTLA-4 (ipilimumab) → more colitis and hypophysitis. Anti-PD-1 (nivolumab/pembrolizumab) → more thyroiditis and pneumonitis. Combination therapy → higher rate AND severity of irAEs (up to 60% grade 3–4 toxicity with ipilimumab + nivolumab). The key is early recognition: any new symptom in a patient on checkpoint inhibitors should prompt you to think "could this be an irAE?" rather than attributing it to infection or disease progression.
TKIs block VEGF receptors (and other kinases), so their toxicity profile reflects the physiological roles of these receptors:
| Side Effect | Mechanism | Details |
|---|---|---|
| Hypertension | VEGF normally promotes nitric oxide (NO) production by endothelial cells → vasodilation. Blocking VEGF → reduced NO → vasoconstriction | Very common (up to 40%); dose-limiting; managed with antihypertensives (ACEi/ARB preferred) |
| Hand-foot syndrome (palmar-plantar erythrodysaesthesia) | Direct toxicity to eccrine glands and capillaries in palms/soles | Painful, erythematous, desquamating skin changes; dose reduction if severe |
| Diarrhoea | Disruption of intestinal mucosal renewal (VEGF/PDGF involved in GI mucosal homeostasis) | Common; managed with loperamide |
| Hypothyroidism | Thyroid capillary regression (VEGF required for thyroid vasculature maintenance) → thyroid ischaemia → destructive thyroiditis → eventual hypothyroidism | Monitor TFTs regularly; treat with levothyroxine |
| Fatigue | Multifactorial (hypothyroidism, anaemia, direct CNS effects) | Very common; most common reason for dose reduction |
| Mucositis/stomatitis | Direct mucosal toxicity | Oral ulcers; managed with mouthwashes, dose reduction |
| Cardiac toxicity | LV dysfunction, QT prolongation; VEGF involved in cardiomyocyte survival | Baseline and interval echocardiography; ECG monitoring |
| Proteinuria/renal toxicity | VEGF is essential for glomerular endothelial health; blocking it → thrombotic microangiopathy in glomeruli | Monitor urinalysis; dose reduce or stop if nephrotic-range proteinuria |
| Hepatotoxicity | Off-target kinase inhibition in hepatocytes | More common with pazopanib; monitor LFTs regularly |
| Bleeding/wound healing impairment | VEGF is essential for angiogenesis in wound healing; blocking it impairs vascular repair | Stop TKI before and after surgery (usually 2–4 weeks); risk of bleeding |
| Side Effect | Mechanism |
|---|---|
| Pneumonitis (non-infectious) | mTOR inhibition → altered immune regulation → hypersensitivity pneumonitis |
| Hyperglycaemia | mTOR is downstream of insulin signalling → inhibition disrupts glucose homeostasis |
| Hyperlipidaemia | mTOR involved in lipid metabolism |
| Mucositis | Direct mucosal toxicity |
| Immunosuppression | mTOR is central to T-cell proliferation → increased infection risk |
Prognosis is estimated using risk stratification models:
| Stage | 5-Year Survival (approximate) |
|---|---|
| Stage I (T1N0M0) | ~90–95% |
| Stage II (T2N0M0) | ~75–85% |
| Stage III (T3/N1) | ~50–65% |
| Stage IV (T4/M1) | ~10–20% (improving with immunotherapy) |
Favourable prognostic factors: early stage, low nuclear grade, clear cell histology (responds to targeted/IO therapy), complete surgical resection, favourable IMDC risk score.
Unfavourable prognostic factors: sarcomatoid differentiation, collecting duct/medullary histology, high nuclear grade, venous invasion, lymph node involvement, metastatic disease at presentation, poor IMDC risk score.
High Yield Summary
Disease Complications:
- Venous invasion (renal vein → IVC → RA) → left varicocele, bilateral LL oedema, ascites, PE, Budd-Chiari syndrome [1].
- Paraneoplastic syndromes (6–10%): hypercalcaemia (PTHrP — most common), polycythaemia (EPO), hypertension (renin), Stauffer syndrome (non-metastatic hepatic dysfunction — reverses post-nephrectomy), cachexia (cytokine-mediated) [1].
- Metastatic disease to lung (cannonball mets), bone (lytic, highly vascular — beware haemorrhage on biopsy), brain, liver, choroid [2].
Surgical Complications: 4. General: bleeding, pneumothorax (pleural injury), injury to adjacent organs (L: spleen, pancreas; R: liver, D2), paralytic ileus (especially transperitoneal approach), wound infection, mortality ~2% [2][3]. 5. Partial nephrectomy-specific: bleeding, urine leakage, ipsilateral recurrence [4]. 6. Radical nephrectomy-specific: temporary or permanent renal failure — the major long-term concern [2][3].
Systemic Therapy Complications: 7. Checkpoint inhibitors: immune-related adverse events (colitis, hepatitis, pneumonitis, thyroiditis, hypophysitis, nephritis). 8. TKIs: hypertension, hand-foot syndrome, diarrhoea, hypothyroidism, cardiac toxicity, proteinuria. 9. mTOR inhibitors: pneumonitis, hyperglycaemia, hyperlipidaemia, immunosuppression.
Active Recall - Complications of RCC
References
[1] Lecture slides: GC 183. Common urological malignancies and their presentations - Nov 7.pdf (pp. 15, 19, 45) [2] Senior notes: felixlai.md (Renal cell carcinoma — Complications section) [3] Senior notes: Ryan Ho Urogenital.pdf (pp. 148–150, Section 7.3.1 — Complications of nephrectomy) [4] Senior notes: maxim.md (Renal cell carcinoma — Management and complications table) [8] Senior notes: Ryan Ho Neurology.pdf (pp. 164–165 — Brain metastasis) [9] Senior notes: Ryan Ho Respiratory.pdf (p. 150 — Secondary tumours of the lungs) [10] Senior notes: Ryan Ho Opthalmology.pdf (p. 59 — Choroidal metastasis) [11] Senior notes: Ryan Ho Endocrine.pdf (p. 44 — Hypercalcaemia of malignancy)
High Yield Summary
- RCC arises from renal tubular epithelium (most commonly proximal tubule → clear cell type, 70–80%).
- Epidemiology: Male > Female, 6th–8th decade, median age 64. In HK: incidence 4.8/100,000.
- Major risk factors: Smoking, obesity, hypertension, acquired cystic kidney disease (30× risk in dialysis patients), VHL syndrome, Birt-Hogg-Dubé, hereditary papillary RCC, tuberous sclerosis.
- VHL pathway is central: Loss of VHL → HIF-α accumulation → VEGF (angiogenesis), EPO (polycythaemia), PDGF (proliferation). This explains the tumour's hypervascularity, anti-VEGF therapy responsiveness, and chemo-resistance.
- Most patients are asymptomatic — 50–60% found incidentally on imaging.
- Classic triad (haematuria + flank pain + palpable mass) = late presentation (10–20%).
- RCC uniquely invades the renal vein and IVC → left varicocele (non-reducing), bilateral LL oedema, PE, ascites.
- Paraneoplastic syndromes (6–10%): polycythaemia (EPO), hypercalcaemia (PTHrP), HTN (renin), Stauffer syndrome (non-metastatic hepatic dysfunction → reversible post-nephrectomy), anaemia of chronic disease.
- Most common metastatic sites: Lung (cannonball mets) > bone (lytic, vascular) > liver > brain > lymph nodes.
- Histological subtypes: Clear cell (70–80%) > papillary (10–15%) > chromophobe (5–10%) > collecting duct (~1%) > medullary (< 1%, sickle cell trait).
High Yield Summary
- Not all renal masses are RCC — ~20% of renal masses are benign (angiomyolipoma, oncocytoma, simple cysts).
- Key imaging feature for AML: macroscopic fat on CT (HU < −20). Key imaging feature for oncocytoma: central stellate scar — but cannot reliably distinguish from chromophobe RCC without histology.
- Bosniak classification guides management of cystic renal masses: I–II = benign (no follow-up), IIF = follow-up, III = indeterminate (~50% malignant), IV = treat as malignant.
- Urothelial carcinoma of the renal pelvis presents as a central filling defect (not a cortical mass) and requires nephroureterectomy, not nephrectomy alone.
- Lymphoma and renal metastasis are treated with systemic therapy — biopsy is indicated to confirm before committing to chemotherapy.
- CT-guided biopsy is traditionally NOT done for suspected RCC (risk of tumour seeding); it is reserved for when the result would change management (suspected lymphoma, metastasis, or non-malignant cause).
- In children: think Wilms' tumour first; differentiate from neuroblastoma with urine catecholamines (VMA/HVA).
- In young adults with sickle cell trait: think renal medullary carcinoma (very aggressive, nearly universally fatal).
- XGP is the great mimicker of RCC — chronic granulomatous infection that often only gets diagnosed after nephrectomy.
High Yield Summary
- There is no serum tumour marker for RCC — diagnosis is imaging-based.
- CT abdomen with contrast (renal protocol) is the gold standard — 90% accuracy for characterising and staging RCC.
- Enhancement > 10–15 HU on post-contrast CT differentiates solid tumour from simple cyst — this is the single most important imaging feature.
- Bosniak classification stratifies cystic renal lesions: I–II = benign, IIF = follow-up, III–IV = surgical excision.
- MRI is indicated when IVC involvement is suspected — to determine the cephalad extent of tumour thrombus (determines surgical approach).
- Tissue diagnosis comes from the nephrectomy specimen — pre-operative biopsy is NOT standard for resectable masses.
- Biopsy indications: suspected lymphoma, suspected metastasis from another primary, non-malignant differential, before thermal ablation, patient preference.
- Staging workup: CT chest (all patients), bone scan (if symptomatic), brain imaging (if neurological symptoms).
- Baseline bloods serve three functions: detect paraneoplastic syndromes (Ca, Hb, EPO), assess organ function pre-operatively (RFT for surgical planning), and provide prognostic information (IMDC criteria: Hb, Ca, neutrophils, platelets).
- RFT is critical pre-operatively — baseline renal function determines whether partial nephrectomy (nephron-sparing) should be preferred over radical nephrectomy.
High Yield Summary
- Surgery is the only cure for localised RCC. Partial nephrectomy is standard for T1 (≤ 7 cm); radical nephrectomy for T2 and above [1].
- Absolute indications for partial nephrectomy: solitary kidney, bilateral tumours, multiple small tumours [2].
- Early ligation of the vascular pedicle during radical nephrectomy is crucial to prevent haemorrhage and tumour dissemination [2][3].
- IVC tumour thrombus above hepatic veins requires cardiopulmonary bypass ± hypothermic circulatory arrest [2][3].
- NO role for adjuvant chemotherapy after complete resection of localised RCC [2][3]. Adjuvant pembrolizumab is now an option for selected high-risk clear-cell RCC after nephrectomy using KEYNOTE-564-style criteria.
- Chemotherapy has NO role in RCC (P-glycoprotein efflux pump; chemo-resistant) [2].
- Radiotherapy is selective: stereotactic RT for brain/bone metastases and SABR/SBRT for selected cT1 patients unfit for surgery.
- Metastatic RCC management is guided by IMDC risk stratification [3]:
- Favourable: IO-TKI, nivolumab + ipilimumab, or TKI monotherapy depending on patient factors
- Intermediate/poor: IO-based combination therapy (nivolumab + ipilimumab, pembrolizumab + axitinib, lenvatinib + pembrolizumab, or nivolumab + cabozantinib)
- Cytoreductive nephrectomy is selective: avoid routine upfront CN in poor-risk patients or intermediate-risk patients needing immediate systemic therapy; consider delayed CN after response or immediate CN when all disease can be locally treated.
- Metastasectomy improves survival in selected patients with oligometastatic, resectable disease [3].
- Active surveillance is safe for elderly/frail patients with tumours < 4 cm (mean growth 3 mm/year, 1–2% metastatic progression) [3].
- Biopsy before thermal ablative therapy (RFA/cryo) is mandatory since no surgical specimen will be available [3].
High Yield Summary
Disease Complications:
- Venous invasion (renal vein → IVC → RA) → left varicocele, bilateral LL oedema, ascites, PE, Budd-Chiari syndrome [1].
- Paraneoplastic syndromes (6–10%): hypercalcaemia (PTHrP — most common), polycythaemia (EPO), hypertension (renin), Stauffer syndrome (non-metastatic hepatic dysfunction — reverses post-nephrectomy), cachexia (cytokine-mediated) [1].
- Metastatic disease to lung (cannonball mets), bone (lytic, highly vascular — beware haemorrhage on biopsy), brain, liver, choroid [2].
Surgical Complications: 4. General: bleeding, pneumothorax (pleural injury), injury to adjacent organs (L: spleen, pancreas; R: liver, D2), paralytic ileus (especially transperitoneal approach), wound infection, mortality ~2% [2][3]. 5. Partial nephrectomy-specific: bleeding, urine leakage, ipsilateral recurrence [4]. 6. Radical nephrectomy-specific: temporary or permanent renal failure — the major long-term concern [2][3].
Systemic Therapy Complications: 7. Checkpoint inhibitors: immune-related adverse events (colitis, hepatitis, pneumonitis, thyroiditis, hypophysitis, nephritis). 8. TKIs: hypertension, hand-foot syndrome, diarrhoea, hypothyroidism, cardiac toxicity, proteinuria. 9. mTOR inhibitors: pneumonitis, hyperglycaemia, hyperlipidaemia, immunosuppression.
Prostate Cancer
Prostate cancer is a malignant neoplasm arising from the glandular epithelial cells of the prostate, most commonly adenocarcinoma, typically affecting older men and often characterized by slow growth and elevated prostate-specific antigen levels.
Testicular Cancer
Testicular cancer is a malignant neoplasm arising from germ cells or, less commonly, stromal cells of the testis, most frequently presenting as a painless scrotal mass in young men aged 15–35 years.